Section 3 of 6
Product information and disease description
395 evidence topics · 153 sources
Product description
Phase of product development
Summary
Mineralys Therapeutics submitted a New Drug Application (NDA) for lorundrostat to the FDA in December 2025 for “the treatment of hypertension in combination with other antihypertensive drugs”. The FDA accepted the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026. The company described the application as still under review in its third quarter 2026 results announcement and in its release on the Transform-HTN results presented on November 8, 2026. According to the company, the NDA includes the pivotal Launch-HTN (phase 3) and Advance-HTN (phase 2) trials, the Explore-CKD proof-of-concept trial, and the Transform-HTN open-label extension trial; the Explore-OSA trial was not part of the original application. In its 2026 Form 10-Q, the company described an advisory committee meeting as “not anticipated currently”. No FDA expedited program designation and no marketing application outside the United States was found. The company has stated no launch date; it describes its commercial preparations as on track for “launch upon approval”. In its third quarter 2025 results announcement, the company had planned the submission for “near the end of 2025 or during the first quarter of 2026”.
Regulatory status: Under review; NDA submitted December 2025, PDUFA target action date December 2026
Launch
No evidence found.
Commercial launch preparation: launch planned upon approval, no date stated
NDA submission, December 2025
Trials included in the NDA
Advisory committee meeting: not anticipated
FDA expedited program designations (Fast Track, Breakthrough Therapy, Priority Review)
No evidence found.
Marketing applications outside the United States
No evidence found.
NDA submission planned for late 2025 or the first quarter of 2026, November 2025, superseded in December 2025
Pivotal Launch-HTN and Advance-HTN topline results, March 2025
Phase 2 Target-HTN topline results, November 2022
First-in-human study by Tanabe, November 2016 to May 2017
“A four‐part, randomized, double‐blind, placebo‐controlled, first‐in‐human study was performed (single‐center in the Netherlands; November 16, 2016–May 01, 2017) to determine the safety, tolerability, PK, and PD of single ascending doses (SADs; part 1) and multiple ascending doses (MADs; part 2) of lorundrostat free base in a capsule in healthy participants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Product information
Generic, brand name and therapeutic class of product
Generic name, chemical name, and identifiers
| Field | Quoted record |
|---|---|
| International nonproprietary name (Latin) | “lorundrostatum” |
| International nonproprietary name (English) | “lorundrostat” |
| Functional description | “aldosterone synthase inhibitor” |
| Molecular formula | “C24H33N7O2” |
| CAS registry number | “1820940-17-7” |
Development codes: MLS-101 and MT-4129
Brand name
No evidence found.
Manufacturer: Mineralys Therapeutics
Originator and license: Tanabe Pharma Corporation
| Field | Quoted record |
|---|---|
| Lead sponsor of the first-in-human study | “Tanabe Pharma Corporation” |
Therapeutic class: oral, highly selective aldosterone synthase inhibitor
Dosage forms and strengths
Investigational dosage form: oral tablet
“The placebo tablets were identical in color, shape, and packaging to the tablets containing lorundrostat. Participants took 2 tablets at each dosing to ensure blinding of dose escalation after week 6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lorundrostat or matching placebo tablets were administered orally once daily at approximately the same time each morning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Doses studied in phase 2 and phase 3 trials: 12.5 mg to 100 mg
“The lorundrostat capsule formulation used in the first‐in‐human studies reported here is equivalent to ~50% of exposure seen in the tablet formulation used in the phase II study (doses used in the phase II study included 12.5 mg once daily and twice daily, 25 mg twice daily, 50 mg once daily, and 100 mg once daily).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Commercial strengths and package sizes
No evidence found.
Average sales price and wholesale acquisition cost
Wholesale acquisition cost and average sales price of lorundrostat
No evidence found.
Lorundrostat price not finalized or disclosed, November 2026
Company pricing frame: branded SGLT2 inhibitor and Entresto price points, March 2026
Price and reimbursement as competitive factors
ICER placeholder price for lorundrostat: baxdrostat wholesale acquisition cost, October 2026
ICER health benefit price benchmark for lorundrostat, October 2026
American hospital formulary service (AHFS), or other drug classification
AHFS classification
No evidence found.
WHO INN functional description: aldosterone synthase inhibitor
Class of the first FDA-approved aldosterone synthase inhibitor, baxdrostat
Indication
Proposed indication: treatment of hypertension in combination with other antihypertensive drugs
Indication wording in the NDA acceptance announcement: adult patients
Target population named by the company: uncontrolled or resistant hypertension
Population of the pivotal trials: blood pressure uncontrolled on two to five antihypertensive medications
Intended line of therapy: third line or later
Pharmacology
Mechanism of action
Selective inhibition of aldosterone synthase (CYP11B2)
“Lorundrostat is a novel molecular entity (Figure 1) designed to target the renin–angiotensin–aldosterone system (RAAS), via inhibition of aldosterone synthase (CYP11B2) resulting in targeted suppression of aldosterone production.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Aldosterone synthase (CYP11B2) is a mitochondrial cytochrome P450 (CYP) enzyme that converts 11‐deoxycorticosterone (11‐DOC) to aldosterone in three consecutive steps” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
In vitro potency and selectivity over 11β-hydroxylase (CYP11B1)
“Lorundrostat inhibited hCYP11B2 and hCYP11B1 with inhibition constant values of 1.27 nmol/L and 475 nmol/L, respectively. These results indicate that lorundrostat inhibits CYP11B2 with 374‐fold selectivity over CYP11B1 (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CYP11B1, a key enzyme in glucocorticoid biosynthesis, has a high homology to CYP11B2 (>93%). High selectivity for CYP11B2 over CYP11B1 is an essential characteristic for a successful aldosterone synthase inhibitor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Osilodrostat, the first aldosterone synthase inhibitor, lacked high selectivity, resulted in blunted adrenocorticotropic hormone‐stimulated cortisol release in some patients, and instead became a treatment for Cushing's disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reduction of circulating aldosterone compared with mineralocorticoid receptor antagonists
“In contrast to mineralocorticoid receptor antagonists (MRAs), lorundrostat is designed to reduce rather than stimulating the substantial increase in circulating aldosterone seen with MRAs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This unique difference is anticipated to reduce adverse non‐MR‐mediated aldosterone signaling via the GPER (GPR30) receptor on blood vessels and other tissues, avoiding the estrogenic side effects of MRAs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Plasma aldosterone suppression after single and multiple doses in healthy participants
“Single doses of lorundrostat, ranging from 10 to 800 mg reduced the AUC0–24 for PAC in a dose‐dependent manner, with statistically significant decreases ranging from 36% to 77% vs. placebo (Figure 2b; Table S5) without effecting cortisol (Figure 2c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PAC (AUC0–24) was reduced by up to 40% with single 100‐ to 200‐mg doses and up to 70% with single 400‐ to 800‐mg doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the lower dose levels (lorundrostat 5–50 mg), the PAC returned to values near baseline within 24 h post‐dose. At the higher dose levels (lorundrostat 100–800 mg), the reduction of PAC was sustained until 24 h post‐dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with the SAD cohorts, multiple‐dose lorundrostat data demonstrated that for all dose levels tested, PAC decreased in an apparent dose‐dependent manner between 2 and 12 h post‐dose on Day 7 (Figure 2d).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aldosterone rebound after discontinuation in healthy participants
“From 24 h after the last dose on Day 7, a clear rebound in PAC ranging from 73% to 163% compared with placebo was observed at all multiple‐dose levels of lorundrostat. These increases were sustained at least until Day 10, 3 days after the last dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From Day 7 to Day 9, clear reductions in the urinary log10 (10 × Na+/K+) ratio were observed, suggesting a rebound effect for the sodium/potassium ratio as well.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Basal and cosyntropin-stimulated cortisol in healthy participants
“During non‐ACTH challenge conditions, no relevant changes from baseline were observed for serum cortisol concentrations and plasma 11‐deoxycortisol concentrations during multiple dosing of lorundrostat. At all multiple‐dose levels, lorundrostat completely blunted the ACTH‐stimulated aldosterone response on Day 6 compared with placebo, while there was no effect on the cortisol response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma renin activity, 11-deoxycorticosterone, serum potassium, and natriuresis in healthy participants
“Once‐daily administration of lorundrostat at doses ranging from 40 to 360 mg increased plasma renin activity and serum 11‐DOC compared with placebo (Figure 3a,b). Elevations in serum potassium concentrations due to lorundrostat‐mediated reductions in PAC were mild and seen across all doses tested (Figure 3c). These effects declined during the washout period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Urine sodium and urinary log10 (10 × Na+/K+) ratio were increased at all dose levels tested in the SAD, consistent with reduced aldosterone signaling (Figure 3d).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within 2 days of initiation of lorundrostat treatment, serum potassium rose in all three dose cohorts (part 2) by group mean values ranging from 0.28 to 0.38 mmol/L and remained elevated throughout the remainder of the 7 days of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given that the PD effects on renal electrolyte regulation were near maximum at 120 mg daily and the excessive 11‐DOC accumulation observed at dose of 360 mg once daily, the data suggest that the dose selection for the treatment of hypertension should avoid the higher dose level and focus on doses up to 120 mg daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aldosterone reduction in participants with hypertension: company summary
Serum aldosterone, plasma renin activity, and cortisol in uncontrolled hypertension: Target-HTN
“Lorundrostat resulted in reductions in serum aldosterone at all doses, whereas the cohort 1 placebo group saw an increase in mean serum aldosterone level of 0.14 (SD, 3.68) ng/dL. The 12.5-mg, 50-mg, and 100-mg once-daily doses in cohort 1 reduced mean serum aldosterone by 1.05 (SD, 4.33) ng/dL, 2.56 (SD, 3.72) ng/dL, and 2.88 (SD, 4.44) ng/dL, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anticipated increases in PRA were observed ranging between 0.78 (SD, 3.44) ng/mL/h to 4.65 (SD, 11.27) ng/mL/h in cohort 1, and there were small increases in serum cortisol” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum aldosterone and plasma renin activity in hypertension with chronic kidney disease: Explore-CKD
Circulating heart failure risk biomarkers: post hoc proteomic analysis of Launch-HTN and Advance-HTN
Cardiac repolarization: concentration-QTc analysis in healthy participants
Cardiac ion channel and nonclinical cardiovascular safety
Pharmacokinetics
Absorption, half-life, and clearance after single doses in healthy participants
“Following single oral doses across 5–800 mg, plasma drug concentration–time profiles demonstrated rapid absorption with a median time to maximum concentration (T max) 1.0–1.5 h (Table 3; Figure 1b); the mean terminal half‐life (t 1/2) ranged from 7.9 to 10.5 h, and apparent clearance was comparable, ranging from 18.7 to 27.6 L/h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The interindividual variability of exposure parameters (C max and AUC0–∞) were low to moderate (<20%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose proportionality
“Over the dose range of 5–800 mg of lorundrostat in part 1, dose proportional increases in systemic exposure in terms of AUC0–∞ were observed as the 95% CIs of the slopes for the AUCs vs. dose included the value 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, the estimate of the slope (95% CI) for C max versus dose was 1.104 (1.043–1.164), and a slightly greater than dose proportional increase in C max was observed over the range 5–800 mg (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, systemic exposure in terms of the AUC0–24 and C max appeared to increase in a slightly more than dose proportional manner over the tested multiple‐dose range on Days 1 and 7 (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Steady state and accumulation with once-daily dosing
“A steady state was achieved by approximately Day 5 and very slight accumulation of lorundrostat was observed following multiple dosing compared with Day 1, with the mean rate of accumulation values for AUC0–24 ranging from 1.15 to 1.19 across the entire dose range. Consistent with single‐dose administration, the mean t 1/2 values on Day 7 ranged from 9.1 to 11.9 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After single‐ and multiple‐dose lorundrostat administration, plasma levels peaked 1–3 h after administration with a t 1/2 of 10–12 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renal excretion of unchanged drug
“After a single dose of 40–360 mg of lorundrostat on Day 1, the fraction of the dose excreted in the urine as unchanged was low, with mean values ranging between 1.2%–1.8%. The fraction of the lorundrostat dose excreted remained consistent over the dose range tested. Renal clearance (CLR) was low and generally similar across dose levels (mean CLR ranging between 0.3–0.5 L/h) after a single dose on Day 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After 7 days of once‐daily doses of lorundrostat, the fraction of the dose excreted in the urine as unchanged drug was low for all multiple‐dose levels, with mean values ranging between 2.3% and 2.6%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Food effect
“Based on the dose escalation data of the first cohort in part 2 where lorundrostat was administered in the fed state, the PK profile did not appear to be affected compared with part 1 where lorundrostat was administered in the fasted state.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Separate from the study we report in this article, a formal food effect study has been conducted and confirms lack of effect of food on the absorption and PK of lorundrostat (tablet formulation; data on file).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relative exposure of the capsule and tablet formulations
Metabolism, protein binding, and volume of distribution
No evidence found.
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information, contraindications, and boxed warnings
Not applicable.
Adverse events of special interest: Launch-HTN
“Prespecified adverse events of special interest included dose reduction, interruption, or discontinuation due to hyperkalemia, hyponatremia, and reduction in kidney function (decline in eGFR) as well as treatment discontinuation due to glucocorticoid deficiency, symptomatic hypotension, severely elevated BP, or overdose of trial drug or prescribed antihypertensive medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prespecified adverse events of hyponatremia, hyperkalemia, and reduction in kidney function (decline in eGFR) were reported more with lorundrostat compared with placebo; however, few treatment discontinuations occurred due to these events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hyperkalemia: Launch-HTN
“A serum potassium level of greater than 6.0 mmol/L occurred in 4 participants (1.5%) randomized to 50 mg of lorundrostat group with possible dose escalation to 100 mg, in 6 participants (1.1%) randomized to 50 mg of lorundrostat, and in 2 participants (0.7%) randomized to placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean serum potassium level increased in the 2 lorundrostat groups but remained within normal range” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hyperkalemia: Advance-HTN
“A potassium level above 6.0 mmol per liter occurred in 5 participants (5%) in the stable-dose group, 7 participants (7%) in the dose-adjustment group, and no participants in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hyperkalemia: Target-HTN
“Mean serum potassium increases were similar across all lorundrostat doses, including increases of 0.25 mmol/L in the 50-mg and 100-mg once-daily groups. Six participants (3.6%) had serum potassium levels above 6.0 mmol/L during the trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No instances of hyperkalemia required intervention beyond discontinuation or reduction in the dose of lorundrostat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lorundrostat has a relatively short half-life, and once-daily dosing resulted in a 25% lower mean change in serum potassium when 50 mg once daily was compared with 25 mg twice daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hyperkalemia: Explore-CKD
Adverse events during 36 weeks of open-label treatment: Transform-HTN
| Event | Lorundrostat (N=632), n (%) |
|---|---|
| Any serious adverse event | “27 (4.3)” |
| Treatment-emergent adverse event leading to study drug withdrawal | “37 (5.9)” |
| Hyperkalemia leading to study drug withdrawal | “10 (1.6)” |
| Hyperkalemia requiring modification of trial drug | “32 (5.1)” |
| Hyponatremia requiring modification of trial drug | “28 (4.4)” |
| Hypotension with symptoms | “13 (2.1)” |
| Serum potassium >6.0 mmol/L confirmed by repeat testing | “16 (2.5)” |
Hyponatremia
“Among participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, treatment discontinuation occurred in 1 (0.37%) due to hyperkalemia, in 1 (0.37%) due to hyponatremia, and in 0 due to reduction in kidney function (decline in eGFR). Among participants in the 50 mg of lorundrostat group, treatment discontinuation occurred in 2 (0.37%) due to hyperkalemia, in 2 (0.37%) due to hyponatremia, and in 3 (0.56%) due to reduction in kidney function (decline in eGFR).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events in Advance-HTN
Decline in estimated glomerular filtration rate
“Creatinine-based eGFR decreased by 9.3% from baseline to week 12 in the 2 lorundrostat groups and increased by 0.4% in the placebo group. Using the cystatin-C–based eGFR formula, eGFR decreased by 5.2% in the 50 mg of lorundrostat group with possible escalation to 100 mg, decreased by 4.1% in the 50 mg of lorundrostat group, and increased by 3.4% in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An acute, reversible decline in eGFR of similar or greater magnitude has also been observed with renin-angiotensin-aldosterone system inhibitors and sodium glucose cotransporter inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Declines in eGFR paralleled the reduction in systolic AOBP and were consistent with expected lowering of intraglomerular pressures” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adrenal insufficiency and cortisol
“The treatment-emergent adverse event of glucocorticoid insufficiency was reported in 0 participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, in 3 participants (0.56%) in the 50 mg of lorundrostat group, and in 5 participants (1.9%) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no reports of hyperadrenocorticism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 12, the geometric mean for serum cortisol increased by 4.2% from baseline in the 50 mg of lorundrostat group with possible escalation to 100 mg, increased by 5.0% in the 50 mg of lorundrostat group, and decreased by 2.0% in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No adrenocortical insufficiency occurred during the trial. Cosyntropin stimulation testing in participants randomized to 100 mg once daily in both cohort 1 and cohort 2 was normal, with stimulated values of cortisol greater than 18 µg/dL in all individuals receiving cosyntropin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events in healthy participants: first-in-human study
“Lorundrostat was well tolerated and no serious TEAEs occurred during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall incidence of TEAEs was comparable between participants treated with lorundrostat (41/87 [47%]) and those treated with placebo (18/29 [62%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of the subjects reached the stopping criterion for potassium of 6.0 mmol/L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company risk factors: adverse effects and labeling
Class context: warnings and precautions for the approved aldosterone synthase inhibitor baxdrostat
Special populations
Older adults: pharmacokinetics in healthy men aged 65 years or older
“In part 4, there was no statistically significant difference between older adult and younger adult lorundrostat exposures (Table S4). The median T max value was earlier for older adult participants (1.0 h) vs. younger adult participants (1.5 h), and the mean t 1/2 value was slightly longer for older adult (11.4 h) than for younger adult (10.0 h) participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In parts 3 and 4, the change from baseline of PAC and serum cortisol concentrations at 24 h after a single 100‐mg dose of lorundrostat was similar in male and female participants, as well as in those aged 18–55 years and aged ≥65 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sex: pharmacokinetics in healthy women
“In part 3 of the study, after a single 100‐mg dose of lorundrostat, there was no statistically significant difference between lorundrostat exposure in females and males (Table S4). The median T max values were comparable for female participants (1.3 h) and male participants (1.5 h), and the mean t 1/2 value was slightly longer for females (12.4 h) than for males (10.0 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age, sex, race, and body mass index: Launch-HTN subgroups
“The efficacy of lorundrostat for lowering BP was consistent across age, sex, race, BMI, and number of prescribed antihypertensive medications participants were taking (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Subgroup | Lorundrostat 50 mg, change in AOSBP at week 6 (mmHg) | Placebo, change in AOSBP at week 6 (mmHg) | Difference (90% CI) |
|---|---|---|---|
| Age ≥75 years | “-18.2” | “-6.6” | “-11.6 (-17.4, -5.8); p=0.0011” |
| Age 65 to 74 years | “-16.7” | “-9.8” | “-6.9 (-11.4, -2.4); p=0.0109” |
| Age <65 years | “-16.9” | “-7.6” | “-9.3 (-13.2, -5.4); p<0.0001” |
| Black or African American | “-15.1” | “-8.3” | “-6.7 (-11.6, -1.9); p<0.0222” |
| White | “-17.1” | “-8.0” | “-9.2 (-12.8, -5.6); p<0.0001” |
| Female | “-16.8” | “-7.4” | “-9.4 (-13.6, -5.3); p=0.0002” |
| Male | “-17.0” | “-8.2” | “-8.8 (-12.6, -5.1); p<0.0001” |
| BMI ≥30 kg/m2 | “-16.5” | “-6.9” | “-9.6 (-13.3, -5.8); p<0.0001” |
| BMI <30 kg/m2 | “-17.9” | “-9.5” | “-8.4 (-12.6, -4.3); p=0.0009” |
Race and ethnicity: first-in-human study population
Obesity: Target-HTN and Advance-HTN
“Most notably, participants with obesity demonstrated greater BP lowering in response to lorundrostat. Individuals with a BMI greater than 30 randomized to 50 mg once daily of lorundrostat demonstrated a −16.7 mm Hg (90% CI, −25.5 to −7.9 mm Hg) change in systolic AOBP compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Key secondary end point | Result |
|---|---|
| Relationship of BMI to blood pressure reduction at 4 weeks | “No clear relationship” |
Renal impairment: low urinary excretion of unchanged drug
Renal impairment: eGFR thresholds for enrollment
“The key exclusion criteria were an estimated glomerular filtration rate (eGFR) of less than 45 mL/min/1.73 m2, a serum potassium level of greater than 5.0 mmol/L at screening or greater than 4.8 mmol/L at randomization, and a serum sodium level of less than 135 mmol/L at screening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic kidney disease stages 1 to 3: Launch-HTN analysis
Chronic kidney disease with albuminuria: Explore-CKD
Hepatic impairment
No evidence found.
Hepatic disease: exclusion from the first-in-human study
Pregnancy and lactation: exclusion from the trials
Drug/Drug, drug/disease interactions
Effects of other drugs on Lorundrostat
Mineralocorticoid receptor antagonists, potassium-sparing diuretics, and epithelial sodium channel inhibitors: prohibited in the trials
“The use of epithelial sodium channel inhibitors, MRAs, and potassium-sparing diuretics was prohibited 4 weeks prior to screening to trial completion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key exclusion criteria included orthostatic hypotension, type 1 diabetes, concomitant use of an epithelial sodium channel inhibitor or MRA, estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2, morning serum cortisol level of less than 3 µg/dL, serum sodium level of less than 135 mmol/L, or hemoglobin A1c of 9% or greater.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Background renin-angiotensin system inhibitors and SGLT2 inhibitors: serum potassium and eGFR
“were placed on a standardized antihypertensive regimen that included a high-dose angiotensin receptor blocker prior to randomization; greater increases in serum potassium level and decreases in eGFR were observed compared with those in the current trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical drug-drug interaction studies
No evidence found.
Effects of Lorundrostat on other drugs
MATE1-dependent transport: competition with creatinine
“The observed decline in eGFR (assessed using the cystatin C–based eGFR formula to correct for falsely elevated creatinine due to competition between lorundrostat and creatinine for MATE [multidrug and toxin extrusion] 1–dependent transport) after initiation of lorundrostat was expected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical drug-drug interaction studies
No evidence found.
Dosing and administration
Dosage
Launch-HTN: 50 mg once daily, with escalation to 100 mg at week 6 in one group
“participants were randomly assigned in a 1:2:1 ratio to receive 50 mg of lorundrostat for 6 weeks and then possibly 100 mg for 6 weeks (n = 270) if they met prespecified criteria at week 6 (the prespecified criteria were office systolic BP ≥130 mm Hg, serum potassium level ≤4.8 mmol/L, serum sodium level ≥135 mmol/L, eGFR >45 mL/min/1.73 m2, and <25% reduction in eGFR from baseline), 50 mg of lorundrostat once daily for 12 weeks (n = 541), or placebo once daily for 12 weeks (n = 272).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 270 participants randomized to 50 mg of lorundrostat once daily, 92 (34.1%) were escalated to the 100-mg dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The trial medication dose could be reduced, temporarily withheld, or permanently discontinued for safety concerns at the discretion of the investigators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing the 50-mg/d dose of lorundrostat to 100 mg/d provided no additional benefit to participants who did not reach the goal BP using the 50-mg/d dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Advance-HTN: 50 mg once daily, or 50 mg increased to 100 mg after 4 weeks
“participants with an average 24-hour ambulatory blood pressure of 130/80 mm Hg or higher were assigned to receive placebo, lorundrostat at a stable dose of 50 mg daily (the stable-dose group), or lorundrostat at a starting dose of 50 mg daily, with an increase to 100 mg daily if systolic blood pressure was 130 mm Hg or higher after 4 weeks (the dose-adjustment group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Target-HTN: dose-ranging from 12.5 mg once daily to 100 mg once daily
“Cohort 1 participants were randomly assigned in a 1:1:1:1:1:1 ratio to placebo or 1 of 5 lorundrostat doses (12.5 mg, 50 mg, or 100 mg once daily or 12.5 mg or 25 mg twice daily).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“randomization to the 2 lowest doses of lorundrostat (12.5 mg once daily and 12.5 mg twice daily) was discontinued due to lack of consistent meaningful reduction of BP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 50-mg once-daily dose of lorundrostat lowered office BP to a similar degree as the 100-mg once daily dose, but resulted in fewer adverse events, including fewer episodes of hyperkalemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transform-HTN: 50 mg once daily, or 25 mg after a dose reduction
Explore-CKD: 25 mg once daily
Doses evaluated in healthy participants
“The dosing cohorts were 5, 10, 20, 50, 100, 200, 400, and 800 mg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The final dose levels of lorundrostat for part 2 were 40, 120, and 360 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proposed labeled dose
No evidence found.
Administration
Oral tablets once daily in the morning: Launch-HTN
“Lorundrostat or matching placebo tablets were administered orally once daily at approximately the same time each morning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants took 2 tablets at each dosing to ensure blinding of dose escalation after week 6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were reminded about taking their trial medication using a smartphone application (AiCure).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration with or without food
“Separate from the study we report in this article, a formal food effect study has been conducted and confirms lack of effect of food on the absorption and PK of lorundrostat (tablet formulation; data on file).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Once-daily compared with twice-daily dosing
“This suggests that allowing an overnight period of escape from aldosterone suppression may have safety benefits when compared with aldosterone synthase inhibitors or aldosterone receptor blockers with longer half-lives, including spironolactone, which has active metabolites with half-lives exceeding 24 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Access and distribution
Commercial launch readiness: sales force, medical affairs, and brand preparation, November 2026
Payer engagement before approval
Anticipated coverage at launch: commercial plans first, Medicare through the exception process
Patient support program
Target prescribers: about 60,000 physicians, 60% primary care and 40% specialty
Manufacturing by third-party contract manufacturers
Specialty pharmacy or limited distribution network
No evidence found.
Sales, marketing, and distribution strategy not yet defined, March 2026, superseded in August 2026
Co-prescribed/Concomitant therapies
Proposed use in combination with other antihypertensive drugs
Launch-HTN: background regimen of 2 to 5 prescribed antihypertensive medications
“Males or females aged 18 years or older with an unattended automated office systolic BP of 135 to 180 mm Hg and diastolic BP of 65 to 110 mm Hg or an isolated automated office diastolic BP of 90 to 110 mm Hg while taking stable doses of 2 to 5 prescribed antihypertensive medications (including a thiazide or thiazide-like diuretic) were eligible for inclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants continued taking their prescribed antihypertensive medications for the duration of the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Launch-HTN: background drug classes and other medications at randomization, No. (%)
Advance-HTN: standardized background regimen of an ARB and a diuretic, with or without a calcium channel blocker
“In this multicenter, double-blind, randomized, placebo-controlled trial, we assigned participants who were receiving two to five antihypertensive medications and had a blood-pressure measurement of 140/90 mm Hg or higher obtained during an office visit to undergo a standardized antihypertensive regimen for 3 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Target-HTN: background therapy and excluded concomitant drugs
“Patients were eligible for trial enrollment if they were older than 18 years with a systolic automated office BP (AOBP) of 130 mm Hg or greater while taking 2 or more antihypertensive medications for at least 4 weeks at maximally tolerated doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key exclusion criteria included orthostatic hypotension, type 1 diabetes, concomitant use of an epithelial sodium channel inhibitor or MRA,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Target-HTN: larger blood pressure reduction with a background thiazide diuretic, November 2022
Explore-CKD: added to an ACE inhibitor or ARB and an SGLT2 inhibitor
Transform-HTN: existing antihypertensive medications continued
Effect of Lorundrostat on quality measures
HEDIS Blood Pressure Control for Patients With Hypertension (BPC-E)
Medicare Part C Star Ratings: Controlling Blood Pressure (C14)
Medicare Part D Star Ratings: Medication Adherence for Hypertension (RAS antagonists) (D09)
Medicare Star Ratings weights of the blood pressure measures, 2027
Product-specific effect on quality measures
No evidence found.
Product comparison
Summary: lorundrostat and the add-on options for uncontrolled hypertension
- Approved add-on drugs with a labeled hypertension indication: baxdrostat (BAXFENDY, aldosterone synthase inhibitor, FDA-approved May 2026, 1 mg or 2 mg once daily), aprocitentan (TRYVIO, endothelin receptor antagonist, 12.5 mg once daily, boxed warning for embryo-fetal toxicity), spironolactone (ALDACTONE, labeled “as add-on therapy for the treatment of hypertension”), and eplerenone (INSPRA, 50 mg once daily, up to 50 mg twice daily). Two renal denervation systems received FDA premarket approval in November 2023 as “adjunctive treatment” when lifestyle modifications and antihypertensive medications do not control blood pressure.
- Placebo-adjusted change in office systolic blood pressure in the pivotal trials: baxdrostat -9.8 mmHg (2 mg) and -8.7 mmHg (1 mg) at week 12 in BaxHTN; aprocitentan 12.5 mg -3.8 mmHg at week 4; lorundrostat 50 mg -9.1 mm Hg at week 6 in Launch-HTN. The trials differ in time point, measurement method, and background therapy, and no head-to-head trial of lorundrostat against another add-on drug was identified.
- Indirect comparisons: in a drug-level network meta-analysis of 10 trials (2,865 participants) with resistant hypertension, the mean differences in office systolic blood pressure versus placebo were -14.08 mmHg (amiloride), -10.78 mmHg (spironolactone), -9.09 mmHg (baxdrostat), -8.14 mmHg (eplerenone), and -6.80 mmHg (lorundrostat). ICER rated the evidence “insufficient” (I) for baxdrostat versus lorundrostat in all three of its populations, “Promising but Inconclusive” (P/I) for either drug versus spironolactone, eplerenone, or amiloride in Populations 1 and 2, and “comparable or inferior” (C-) versus amlodipine in Population 3.
- Hyperkalemia in ICER's comparison table: baxdrostat 6.6% (1 mg) and 10.2% (2 mg) against 2.5% with placebo; lorundrostat 50 mg 2.5% against 0.3% with placebo.
Lorundrostat: Launch-HTN primary endpoint, for comparison with the add-on drugs below
“For the pooled 50 mg of lorundrostat group (n = 808), the least-squares mean change in automated office systolic BP at week 6 was −16.9 mm Hg (95% CI, −19.0 to −14.9 mm Hg) vs −7.9 mm Hg (95% CI, −11.5 to −4.2 mm Hg) for the placebo group (least-squares mean difference, −9.1 mm Hg [95% CI, −13.3 to −4.9 mm Hg]; P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baxdrostat (BAXFENDY, AstraZeneca): FDA approval, May 2026
Baxdrostat (BAXFENDY): prescribing information
Baxdrostat: BaxHTN primary endpoint in the prescribing information, seated systolic blood pressure at week 12
| Systolic blood pressure (mmHg) | BAXFENDY 2 mg | BAXFENDY 1 mg | Placebo |
|---|---|---|---|
| Participants | “n=266” | “n=264” | “n=263” |
| Baseline (mean) | “149.1” | “149.7” | “149.0” |
| Change from baseline (mean) | “-15.7” | “-14.5” | “-5.8” |
| Difference from placebo (95% CI) | “-9.8 (-12.6, -7.0)” | “-8.7 (-11.5, -5.8)” | |
| p-value vs. placebo | “< 0.0001” | “< 0.0001” |
Baxdrostat: BaxHTN publication
“794 participants were randomized to and received baxdrostat 1mg (n=264), baxdrostat 2mg (n=266), or placebo (n=264) in addition to background therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Estimated treatment differences for baxdrostat 1mg and 2mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and – 9.8 mmHg (–12.6 to –7.0; P<0.0001), respectively. Potassium >6.0 mmol/l occurred in 6 participants (2.3%) with baxdrostat 1mg, 8 (3.0%) with baxdrostat 2mg, and 1 (0.4%) with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baxdrostat: Bax24 trial, 24-hour ambulatory systolic blood pressure in resistant hypertension
“At 12 weeks, the change from baseline in the least-squares mean 24 h ambulatory SBP was -16·6 mm Hg (95% CI -18·8 to -14·3) in the baxdrostat group (n=89) and -2·6 mm Hg (-4·7 to -0·4) in the placebo group (n=95); the estimated placebo-corrected difference was -14·0 mm Hg (-17·2 to -10·8; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A confirmed potassium level of more than 6 mmol/L occurred in three (3%) of the 108 baxdrostat recipients and in none of the placebo recipients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baxdrostat: adverse reactions in the pooled 12-week placebo-controlled periods
Baxdrostat: CHMP positive opinion in the European Union, November 2026
Baxdrostat: anticipated FDA action date, December 2025, superseded by approval in May 2026
Aprocitentan (TRYVIO, Idorsia): prescribing information
Aprocitentan: PRECISION primary endpoint in the prescribing information, sitting systolic blood pressure at week 4
| Sitting systolic blood pressure (mmHg) | TRYVIO 12.5 mg | Placebo |
|---|---|---|
| Participants | “243” | “244” |
| Baseline | “153.2” | “153.3” |
| LS mean change (97.5% CL) | “−15.4 (−17.5, −13.3)” | “−11.6 (−13.7, −9.5)” |
| Difference to placebo, LS mean (97.5% CL) | “−3.8 (−6.8, −0.8)” | “–” |
| p-value | “0.0043” | “–” |
Aprocitentan: REMS removed, April 2025
Aprocitentan: commercial availability and approvals outside the United States
Spironolactone (ALDACTONE): prescribing information
Spironolactone: PATHWAY-2 trial in drug-resistant hypertension
“The average reduction in home systolic blood pressure by spironolactone was superior to placebo (–8·70 mm Hg [95% CI −9·72 to −7·69]; p<0·0001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In six of the 285 patients who received spironolactone, serum potassium exceeded 6·0 mmol/L on one occasion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eplerenone (INSPRA): prescribing information
| Field | Quoted label text |
|---|---|
| Indication | “INSPRA is indicated for the treatment of hypertension in adults, to lower blood pressure.” |
| Dosage in hypertension | “The recommended starting dose of INSPRA is 50 mg administered once daily.” |
| Dose increase | “For patients with an inadequate blood pressure response to 50 mg once daily increase the dosage of INSPRA to 50 mg twice daily.” |
| Contraindications for hypertension | “type 2 diabetes with microalbuminuria,” |
| Contraindications for hypertension | “creatinine clearance <50 mL/min, or” |
| Mechanism | “Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone” |
Amiloride: randomized comparison with spironolactone in resistant hypertension
“In this open-label, blinded end-point, randomized clinical trial involving 118 patients with resistant hypertension, amiloride and spironolactone lowered home-measured systolic blood pressure by 13.6 mm Hg and 14.7 mm Hg from baseline, respectively, with no difference in blood pressure–lowering effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vicadrostat (BI 690517, Boehringer Ingelheim): investigational aldosterone synthase inhibitor studied with empagliflozin
“BI 690517 dose-dependently reduced albuminuria with concurrent renin-angiotensin system inhibition and empagliflozin, suggesting an additive efficacy for chronic kidney disease treatment without unexpected safety signals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Zilebesiran (Alnylam and Roche): investigational subcutaneous siRNA against angiotensinogen
“The least-squares mean difference between zilebesiran and placebo in change from baseline to 3 months in 24-hour mean ambulatory SBP was −12.1 mm Hg (95% CI, −16.5 to −7.6; P < .001) for indapamide, −9.7 mm Hg (95% CI, −12.9 to −6.6; P < .001) for amlodipine, and −4.5 mm Hg (95% CI, −8.2 to −0.8; P = .02) for olmesartan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across cohorts, more patients who received zilebesiran than placebo experienced hyperkalemia (18 [5.5%] vs 6 [1.8%]), hypotension (14 [4.3%] vs 7 [2.1%]), and acute kidney failure (16 [4.9%] vs 5 [1.5%]) events, but most episodes were mild and resolved without medical intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LSM differences vs placebo in change from baseline to month 3 were −14.1 mm Hg (95% CI, −19.2 to −9.0; P < .001) with zilebesiran, 150 mg, once every 6 months; −16.7 mm Hg (95% CI, −21.2 to −12.3; P < .001) with zilebesiran, 300 mg, once every 3 months or every 6 months; and −15.7 mm Hg (95% CI, −20.8 to −10.6; P < .001) with zilebesiran, 600 mg, once every 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renal denervation: FDA premarket approvals, November 2023
Renal denervation: Medicare coverage with evidence development
Renal denervation: sham-controlled trials
“At 24 months, the RDN group experienced significantly greater mean reductions in ambulatory systolic BP (−12.1±15.3 mm Hg [n=176] versus −7.0±13.1 mm Hg [n=33]; difference: −5.7 mm Hg; P=0.039) and office systolic BP (−17.4±16.1 mm Hg [n=187] versus −9.0±19.4 mm Hg [n=35]; difference: −8.7 mm Hg; P=0.0034) compared with sham controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The reduction in daytime ambulatory SBP was greater with ultrasound renal denervation (mean, −7.9 mm Hg [SD, 11.6 mm Hg]) vs the sham procedure (mean, −1.8 mm Hg [SD, 9.5 mm Hg]) (baseline-adjusted between-group difference, −6.3 mm Hg [95% CI, −9.3 to −3.2 mm Hg], P < .001), with a consistent effect of ultrasound renal denervation throughout the 24-hour circadian cycle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Drug-level network meta-analysis in resistant hypertension: office systolic blood pressure
“Ten RCTs including 2865 participants were analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MDs versus placebo were −14.08 mmHg for amiloride (95% CI, −17.40 to −10.77), −10.78 mmHg for spironolactone (95% CI, −13.14 to −8.42), −9.09 mmHg for baxdrostat (95% CI, −11.29 to −6.88), −8.14 mmHg for eplerenone (95% CI, −14.56 to −1.72), and −6.80 mmHg for lorundrostat (95% CI, −8.47 to −5.13).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MDs were −10.88 mmHg for MRAs (95% CI, −13.29 to −8.48) and −7.56 mmHg for ASIs (95% CI, −9.24 to −5.89).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although newer ASIs may provide meaningful short‐term BP reductions, equivalence with MRAs cannot be inferred from the current evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, safety outcomes were not quantitatively compared because adverse event reporting was incomplete and inconsistent across trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Indirect comparison of lorundrostat and baxdrostat by the Bucher method
“Five placebo-controlled RCTs (N = 2599) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lower-dose pair was statistically equivalent (lorundrostat 50 mg vs. baxdrostat 1 mg: mean difference (MD), +0.63 mmHg; P = 0.645); baxdrostat 2 mg produced a modest but significant advantage over lorundrostat 100 mg (MD, +3.56 mmHg; P = 0.043).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both agents markedly increased hyperkalemia risk (lorundrostat pooled risk ratio (RR), 8.16; baxdrostat pooled RR, 15.12); the between-drug comparison was not significant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bayesian meta-analysis of second-generation aldosterone synthase inhibitors
“Eight RCTs were included (n = 3,369; 2,430 [72%] randomized to ASI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, ASIs increased the odds of hyperkalemia (OR: 7.1; CrI: 3.56, 15.2; τ2 0.23), hyponatremia (OR: 2.6; CrI: 1.25, 5.98; τ2 0.1), and hypotension (OR: 3.28; CrI: 1.43, 8.16; τ2 0.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In subgroup analysis, the probability of achieving a clinically meaningful reduction in SBP (MD < −5 mm Hg) was 87.5% with baxdrostat and 94.3% with lorundrostat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ICER network meta-analysis, Population 1 (resistant hypertension not at goal): systolic blood pressure versus placebo
| Add-on drug | Mean difference versus placebo, mm Hg (95% credible interval) |
|---|---|
| Baxdrostat | “-11 (-14.6, -7.3)” |
| Spironolactone | “-10.1 (-13.1, -6.8)” |
| Lorundrostat | “-9 (-16.3, -1.7)” |
| Eplerenone | “-8.9 (-15.5, -2.4)” |
| Amiloride | “-6.6 (-11.5, -1.5)” |
ICER network meta-analysis, Population 3 (not at goal on two drugs, third first-line agent not yet tried): systolic blood pressure versus placebo
| Add-on drug | Mean difference versus placebo, mm Hg (95% credible interval) |
|---|---|
| Baxdrostat | “-10.1 (-16.6, -3.9)” |
| Lorundrostat | “-8.6 (-12.4, -4.8)” |
| Amlodipine | “-8.3 (-10.7, -6.2)” |
ICER comparative evidence ratings
Hyperkalemia at 12 weeks across aldosterone-pathway drugs
| Drug | Arm | n | Hyperkalemia, % |
|---|---|---|---|
| Baxdrostat | “BAX 1 mg” | “333” | “6.6” |
| Baxdrostat | “BAX 2 mg” | “441” | “10.2” |
| Baxdrostat | “Placebo” | “442” | “2.5” |
| Lorundrostat | “LOR 50 mg” | “635” | “2.5” |
| Lorundrostat | “Placebo” | “367” | “0.3” |
| Spironolactone | “SPIR 15-50 mg” | “2748” | “17.5” |
| Spironolactone | “Placebo” | “2760” | “7.5” |
| Eplerenone | “EPL 25-50 mg” | “5282” | “5” |
| Eplerenone | “Placebo” | “5275” | “2.6” |
Drug costs used by ICER for the comparators
Place of product in therapy
Disease description
Definition and etiology
Blood pressure categories: 2025 AHA/ACC guideline
Treatment goal and controlled hypertension
Uncontrolled hypertension: definition in a US real-world prevalence study
Resistant hypertension definition: 2025 AHA/ACC guideline
Controlled, uncontrolled, and apparent treatment-resistant hypertension: AHA scientific statement
“RH is defined as the BP of a hypertensive patient that remains elevated above goal despite the concurrent use of 3 antihypertensive agents of different classes, commonly including a long-acting calcium channel blocker (CCB), a blocker of the renin-angiotensin system (angiotensin-converting enzyme [ACE] inhibitor or angiotensin receptor blocker [ARB]), and a diuretic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RH also includes patients whose BP achieves target values on ≥4 antihypertensive medications, a condition that has been referred to in the literature as controlled RH. Thus, the term RH refers to hypertension with both uncontrolled and controlled BP, depending on the number of antihypertensive agents used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The term apparent treatment RH (aTRH) is used when ≥1 of the following data elements are missing: medication dose, adherence, or out-of-office BP; thus, pseudoresistance cannot be excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resistant hypertension definition: European guidelines
Etiology of primary hypertension: behavioral, environmental, hormonal, and genetic factors
Risk factors and demographic correlates of resistant hypertension
Secondary hypertension: settings and common causes
Primary aldosteronism: definition and adrenal subtypes
Primary aldosteronism prevalence by hypertension severity: 2025 AHA/ACC guideline
Primary aldosteronism in resistant hypertension: cohort studies with confirmatory testing
“Mean adjusted levels of urinary aldosterone were 6.5 μg/24 h (95% CI, 5.2 to 7.7 μg/24 h) in normotension, 7.3 μg/24 h (CI, 5.6 to 8.9 μg/24 h) in stage 1 hypertension, 9.5 μg/24 h (CI, 8.2 to 10.8 μg/24 h) in stage 2 hypertension, and 14.6 μg/24 h (CI, 12.9 to 16.2 μg/24 h) in resistant hypertension; corresponding adjusted prevalence estimates for biochemically overt primary aldosteronism were 11.3% (CI, 5.9% to 16.8%), 15.7% (CI, 8.6% to 22.9%), 21.6% (CI, 16.1% to 27.0%), and 22.0% (CI, 17.2% to 26.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over 20 years, we studied 1616 patients with resistant hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of salt suppression tests, 182 (11.3%) patients had primary hyperaldosteronism, and response to spironolactone treatment further confirmed this diagnosis. Hypokalaemia was seen only in 83 patients with primary hyperaldosteronism (45.6%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this prospective study of 88 consecutive patients referred to a university clinic for resistant hypertension, we determined the 24-hour urinary aldosterone excretion during high dietary salt ingestion, baseline plasma renin activity, and plasma aldosterone in all subjects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eighteen subjects (20%) were confirmed to have primary hyperaldosteronism. The prevalence of hyperaldosteronism was similar in black and white subjects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary aldosteronism in resistant hypertension: review estimates
“Primary aldosteronism (PA) is the leading cause of secondary hypertension, affecting at least 10% of all hypertensive patients and up to 25% of those with treatment-resistant hypertension, and is associated with markedly increased cardiovascular, metabolic, and kidney morbidity due to the systemic effects of excess aldosterone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aldosterone dysregulation in uncontrolled and resistant hypertension: company statement
Obstructive sleep apnea and renovascular disease in resistant hypertension
“Very high proportions (60%−84%) of individuals with RH have sleep apnea.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hypertension accelerated or worsened by renal artery stenosis remains among the most common causes of RH, particularly in older age groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of hypertension
Lifetime risk of hypertension: US pooled cohorts
“Data from 13 160 participants in cohorts in the Cardiovascular Lifetime Risk Pooling Project (ie, the Framingham Offspring Study, CARDIA, and ARIC) showed that the lifetime risk of hypertension from 20 to 85 years of age according to the 2017 Hypertension Clinical Practice Guidelines was 86.1% (95% CI, 84.1%–88.1%) for Black males, 85.7% (95% CI, 84.0%–87.5%) for Black females, 83.8% (95% CI, 82.5%–85.0%) for White males, and 69.3% (95% CI, 67.8%–70.7%) for White females.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cumulative incidence of hypertension by age 55 years: CARDIA
“Among 3890 participants without hypertension at baseline (aged 18–30 years), cumulative incidence of hypertension by age 55 years was 75.5%, 75.7%, 54.5%, and 40.0% in black men, black women, white men, and white women, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incidence of resistant hypertension after starting treatment: two US integrated health plans
“Among 205,750 patients with incident hypertension, 1.9% developed resistant hypertension within a median 1.5 years from initial treatment, or 0.7 cases per 100 person-years of follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with incident hypertension started on treatment, 1 in 50 patients developed resistant hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, we have shown that approximately 1 in 6 patients on 3 or more hypertension medications will continue to meet criteria for resistant hypertension over follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incidence of apparent treatment-resistant hypertension: Thai hospital cohort, 2010 to 2024
“Among 114,364 hypertensive patients, the incidence of aRHT was 2.61 per 100 person-years (95% confidence interval [CI], 2.56–2.65).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among HT patients who were initially complication-free, the probabilities of developing aRHT were 9.63% (95% CI, 9.39–9.88) at 5 years and 15.19% (95% CI, 14.80–15.59) at 10 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of hypertension
Hypertension prevalence: NHANES August 2021 to August 2023
Awareness, treatment, and control: NHANES August 2021 to August 2023
Hypertension prevalence, uncontrolled blood pressure, and race: CDC
Treated but uncontrolled hypertension: Million Hearts cascade, NHANES 2017 to 2020
Blood pressure control trends: NHANES 1999 to 2018
“In this serial cross-sectional study that included 18 262 US adults aged 18 years or older with hypertension, with data weighted to be representative of the US population, the age-adjusted estimated proportion with controlled blood pressure increased from 31.8% in 1999-2000 to 48.5% in 2007-2008, remained stable through 2013-2014 (53.8%), and then declined to 43.7% in 2017-2018.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among adults taking antihypertensive medication, the age-adjusted estimated proportion with controlled BP increased from 53.4% (95% CI, 49.0%-57.9%) in 1999-2000 to 68.3% (95% CI, 65.9%-70.8%) in 2007-2008, remained stable and was 72.2% (95% CI, 68.6%-75.8%) in 2013-2014, and then declined to 64.8% (95% CI, 61.3%-68.3%) in 2017-2018 (part B in the Figure).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uncontrolled hypertension above goal: ICER
Apparent treatment-resistant hypertension: NHANES 2003 to 2020
“Apparent treatment resistant hypertension (aTRH) was defined as patients on a diuretic, either with a systolic blood pressure (BP) ≥130 or diastolic BP ≥80 mmHg while on 3 medications or those on ≥ 4 medications regardless of BP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 24,579 adults with HTN, 1,939 had aTRH (42.4% male, 19.9% Black), corresponding to a weighted total of 6,989,821 US patients. Among hypertensive adults, the prevalence of aTRH was 6.41% (95% CI 5.97-6.88%) and remained stable over time. Over the study duration, aTRH prevalence among adults on treatment decreased from 17.7% to 12.6%. The overall prevalence of hypertension rose from 50.1% to 54.0%, while the prevalence of uncontrolled BP decreased from 75.0% to 68.7%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“aTRH was most strongly associated with older patients, those of Black race, higher BMI, and more advanced cardiovascular comorbidities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Apparent treatment-resistant hypertension: NHANES 2009 to 2014, 2008 and 2018 AHA definitions
“The prevalence of aTRH was 17.7% and 19.7% according to the 2008 and 2018 Scientific Statement definitions, respectively (Δ=2.0%; 95%CI 1.5%, 2.7%). Overall, 10.3 million US adults had aTRH according to the 2018 Scientific Statement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resistant hypertension prevalence: guideline and scientific statement estimates
“Among treated adults with hypertension, prevalent aTRH occurs in ≈12% to 15% of population-based” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“and 15% to 18% of clinic-based reports.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Controlled and uncontrolled resistant hypertension: Kaiser Permanente Southern California
“Resistant hypertension was identified in 60,327 (12.8%) individuals of whom 23,104 met our criteria for cRH and 37,223 met our criteria for uRH. Thus, uRH accounted for 61.7% of the resistant hypertension population and 7.9% of all hypertensive individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uncontrolled and resistant hypertension: US real-world patient funnel, Optum Market Clarity, 2018 to 2025
Global resistant hypertension prevalence: meta-analysis of 91 studies
“In the general, population of treated patients with hypertension, the prevalence of true-resistant, apparent treatment-resistant and pseudo-resistant hypertension were 10.3% (95% CI 7.6% to 13.2%), 14.7% (95% CI 13.1% to 16.3%) and 10.3% (95% CI 6.0% to 15.5%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global hypertension prevalence, treatment, and control
“The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
Blood pressure and vascular mortality: one million adults in 61 prospective studies
“At ages 40-69 years, each difference of 20 mm Hg usual SBP (or, approximately equivalently, 10 mm Hg usual DBP) is associated with more than a twofold difference in the stroke death rate, and with twofold differences in the death rates from IHD and from other vascular causes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Throughout middle and old age, usual blood pressure is strongly and directly related to vascular (and overall) mortality, without any evidence of a threshold down to at least 115/75 mm Hg.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
US mortality attributed to high blood pressure
“The 2022 age-adjusted death rate attributable primarily to HBP was 31.5 per 100 000.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From 2012 to 2022, the age-adjusted death rate attributable to HBP increased 63.2%, and the actual number of deaths attributable to HBP rose 93.0%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When any mention of HBP was present, the overall age-adjusted death rate in 2022 was 163.1 per 100 000.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hypertensive emergency: in-hospital and one-year outcomes
Resistant hypertension prognosis: guideline statements
“Importantly, it has been demonstrated that patients with resistant hypertension are at a higher risk of end-organ damage and have a nearly 50% greater risk for cardiovascular events and mortality as compared to those with non-resistant disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resistant hypertension prognosis: incident treated hypertension in two US health plans
“Over 3.8 years of median follow-up, cardiovascular event rates were significantly higher in those with resistant hypertension (unadjusted: 18.0% vs. 13.5%, p<0.001). After adjusting for patient and clinical characteristics, resistant hypertension was associated with a higher risk of cardiovascular events (HR 1.47, 95% CI 1.33–1.62).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resistant hypertension prognosis: renal, cardiovascular, and mortality outcomes in 470,386 individuals
“Resistant hypertension (cRH and uRH) compared to non-RH, had multivariable adjusted hazard ratios (95% confidence intervals) of 1.32 (1.27–1.37), 1.24 (1.20–1.28), 1.46 (1.40–1.52), 1.14 (1.10–1.19), and 1.06 (1.03–1.08) for ESRD, IHE, CHF, CVA, and mortality, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The risk of ESRD and CVA and were 25% and 23% greater, respectively, in uRH compared to cRH supporting the linkage between blood pressure and both outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resistant hypertension prognosis: ambulatory confirmation and mortality, Spanish ABPM registry
“Compared with controlled hypertension, resistant hypertension was associated with an increased risk in all-cause (HR, 1.21 [95% CI, 1.12-1.30]) and cardiovascular mortalities (HR, 1.33 [95% CI, 1.17-1.51]) in confounder-adjusted models.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“When ABPM-confirmed and white-coat resistant hypertension were separately compared with controlled hypertension, only the former was associated with an increased risk of death and cardiovascular death (HR, 1.36 [95% CI, 1.26-1.48] and 1.56 [95% CI, 1.36-1.79]), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Resistant hypertension prognosis: Thai hospital cohort
“Regarding the prognosis of aRHT, compared to non-aRHT patients, those with aRHT had significant higher risk of CAD, CKD, HF, and all-cause mortality with hazard ratios (95% CI) of 1.80 (1.56–2.08), 1.93 (1.79–2.08), 4.24 (3.54–5.08), and 2.84 (1.89–4.27), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of blood pressure control within resistant hypertension
“Prospective studies using ABPM have suggested an almost 2-fold increased risk of CVD events in patients with true RH compared with those with hypertension responsive to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BP control reduced the risk of incident stroke, coronary heart disease, or heart failure by 13% among those with RH compared with a 31% lower risk of these outcomes among patients without RH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality with hypertension uncontrolled on two or more medications: company statement
Pathophysiology
Primary aldosteronism: renin-independent aldosterone production and volume expansion
Continuum of renin-independent aldosterone production across blood pressure categories
“Participants with normotension (n = 289), stage 1 hypertension (n = 115), stage 2 hypertension (n = 203), and resistant hypertension (n = 408).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Every blood pressure category had a continuum of renin-independent aldosterone production, where greater severity of production was associated with higher blood pressure, kaliuresis, and lower serum potassium levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean adjusted levels of urinary aldosterone were 6.5 μg/24 h (95% CI, 5.2 to 7.7 μg/24 h) in normotension, 7.3 μg/24 h (CI, 5.6 to 8.9 μg/24 h) in stage 1 hypertension, 9.5 μg/24 h (CI, 8.2 to 10.8 μg/24 h) in stage 2 hypertension, and 14.6 μg/24 h (CI, 12.9 to 16.2 μg/24 h) in resistant hypertension” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Beyond this categorical definition of primary aldosteronism, there is a prevalent continuum of renin-independent aldosterone production that parallels the severity of hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mineralocorticoid receptor activation and target organ injury
“This renin-independent aldosterone production can cause hypertension, but interactions with the mineralocorticoid receptor also cause hypokalemia and increased risk for adverse cardiovascular outcomes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Chronic renin-angiotensin-aldosterone system activation and excess aldosterone exert detrimental effects on the heart and the kidneys via contributing to inflammation, fibrosis, and dysfunction in the myocardium, vasculature, and the kidneys.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These effects are purported to be through genomic mineralocorticoid receptor (MR)-mediated, nongenomic MR-dependent, and nongenomic non-MR dependent actions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because both hyperkalemia and excess aldosterone are associated with progression of CKD and HF, and MRA therapy is associated with elevations in aldosterone levels, patients on MRA therapy may remain at a high residual risk for poor outcomes even on MRA therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aldosterone excess and intravascular volume expansion in resistant hypertension
“Consecutive subjects with resistant hypertension (RHTN) (n=279) and controls (n=53) were prospectively evaluated for plasma aldosterone (PAC), plasma renin activity (PRA), aldosterone-renin ratio (ARR), brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), 24-hr urinary aldosterone (UAldo), cortisol (UCort), sodium (UNa) and potassium (UK) on their routine diet.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PAC (13±0.5 vs. 8.4±0.7 ng/dl, p=0.0005), ARR (22±1.7 vs. 6±0.7, p < 0.0001), UAldo (13±0.6 vs. 9.7±0.9 μg/24hr, p=0.02), BNP (37.2±3.1 vs. 22.5±3.4 pg/ml, p=0.007) and ANP (95.9±5.8 vs. 54.8±4.9 pg/ml, p=0.001) were higher, PRA (2.3±0.2 vs. 3.8±0.9 ng/ml/hr, p=0.02) and serum potassium (3.9±0.03 vs. 4.3±0.06 mEq/L, p < 0.0001) were lower in patients with RHTN compared to controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings indicate that aldosterone levels are higher and there is evidence of intravascular volume expansion (higher BNP and ANP levels) in patients with resistant hypertension compared to controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renin suppression and sodium retention in resistant hypertension
“and suppressed circulating renin levels (≈60% of those with RH have suppressed renin levels).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In general, RH is characterized by exquisite salt sensitivity of BP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Home systolic blood pressure reduction by spironolactone was predicted by ARR (r2=0·13, p<0·0001) and plasma renin (r2=0·11, p=0·00024).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, 31 (25% [95% CI 17–33]) of 126 patients were deemed to have inappropriately high aldosterone concentrations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thoracic fluid content was reduced by 6·8% from baseline (95% CI 4·0 to 8·8; p<0·0001) with spironolactone, but not other treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our results suggest that resistant hypertension is commonly a salt-retaining state, most likely due to inappropriate aldosterone secretion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mineralocorticoid receptor blockade by spironolactone overcomes the salt retention and resistance of hypertension to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obesity: visceral adiposity and mineralocorticoid activity
“Visceral adiposity in particular plays a fundamental role in causing high BP through a variety of mechanisms culminating in enhanced salt sensitivity, vascular dysfunction, and activation of the sympathetic nervous system and renin-angiotensin system.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mounting evidence further supports the importance of heightened mineralocorticoid activity in RH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic kidney disease: impaired sodium excretion and volume expansion
“CKD is both a cause and a complication of poorly controlled hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reduced kidney function results in impaired salt excretion, overactivation of the renin-angiotensin-aldosterone system, increased sympathetic nervous system activity, and altered medication efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment resistance in patients with CKD is undoubtedly related in large part to increased sodium and fluid retention and consequential intravascular volume expansion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obstructive sleep apnea: fluid retention and aldosterone excess
“OSA is extremely common in patients with RH, with prevalence rates as high as 70% to 90%, and when present, OSA is often severe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The high occurrence of OSA in patients with RH has been attributed to increased fluid retention and accompanying upper airway edema, as suggested by studies positively relating the presence and severity of OSA to aldosterone excess and high dietary sodium intake.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The role of aldosterone in promoting OSA is additionally supported by studies demonstrating that mineralocorticoid receptor antagonists reduce the severity of OSA in patients with RH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Office blood pressure measurement: standardized protocol
Out-of-office blood pressure: home and ambulatory monitoring
Pseudoresistance: confirmation of true treatment resistance
“Assessment for treatment adherence and use of ABPM (or home BP monitoring if ABPM is unavailable) are needed to confirm RH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaccurate measurement of BP can result in the appearance of treatment resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this study of patients referred for RH, inaccurate BP measurement was estimated at 33%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
White-coat effect in apparent treatment-resistant hypertension
“A clinically significant white-coat effect may be present in 28% to 39% of individuals with aTRH by office BP measurement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among them, 8295 (12.2% of the database) had resistant hypertension (office blood pressure ≥140 and/or 90 mm Hg while being treated with ≥3 antihypertensive drugs, 1 of them being a diuretic).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After ambulatory blood pressure monitoring, 62.5% of patients were classified as true resistant hypertensives, the remaining 37.5% having white-coat resistance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medication nonadherence: prevalence and adherence testing
“From an initial discovery of 921 studies, we identified 24 studies that measured medication adherence for patients with uncontrolled BP despite being prescribed three or more antihypertensive medications of different classes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“the pooled prevalence of nonadherence was 31.2%” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“with nonadherence rates ranging from 3.3 to 86.1%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The strongest contributor to variance in nonadherence rates was the method of adherence assessment used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There is no gold standard for measuring adherence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A direct method such as urine or blood measurement of drug or metabolites is considered more robust but is relatively expensive, is of limited availability, and does not perfectly reflect level of adherence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary aldosteronism screening: 2025 Endocrine Society guideline
“We suggest that all individuals with hypertension be screened for PA by measuring aldosterone and renin and determining the aldosterone to renin ratio, and that subsequent clinical care be guided by the results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“the 2025 Endocrine Society guideline extends screening recommendations beyond high-risk subgroups to encompass all adults with hypertension, issuing a conditional (Grade 2) recommendation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Specifically, a positive screen is defined by a suppressed renin – plasma renin activity (PRA) ≤1 ng/mL/h or direct renin concentration (DRC) ≤8.2 mU/L – in combination with inappropriately elevated aldosterone (≥10 ng/dL by immunoassay or ≥7.5 ng/dL by liquid chromatography), and an elevated ARR (aldosterone [ng/dL] to PRA [ng/mL/h] ratio >20 or aldosterone [pmol/L] to DRC [mU/L] ratio >70).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary aldosteronism screening: 2025 AHA/ACC guideline
Primary aldosteronism screening: sensitivity of the aldosterone-to-renin ratio
Primary aldosteronism screening rates in practice
Clinical presentation - signs and symptoms
Asymptomatic presentation: elevated blood pressure without signs or symptoms
Target organ damage: heart, vasculature, kidneys, brain, and retina
“The former group was younger, more frequently men, with a longer duration of hypertension and a worse cardiovascular risk profile.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The group included larger proportions of smokers, diabetics, target organ damage (including left ventricular hypertrophy, impaired renal function, and microalbuminuria), and documented cardiovascular disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Acute presentation: hypertensive emergency
Sleep-related symptoms: obstructive sleep apnea
“Very high proportions (60%−84%) of individuals with RH have sleep apnea.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“clinicians should vigorously screen such patients for symptoms of OSA (loud snoring, frequent nocturnal arousals, witnessed apnea, and excessive daytime sleepiness) and have a low threshold for referral for definitive evaluation and treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Electrolyte signs: hypokalemia in primary aldosteronism
“On the basis of salt suppression tests, 182 (11.3%) patients had primary hyperaldosteronism, and response to spironolactone treatment further confirmed this diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Hypokalaemia was seen only in 83 patients with primary hyperaldosteronism (45.6%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Circadian blood pressure pattern: nocturnal nondipping
Paroxysmal symptoms: pheochromocytoma and paraganglioma
“The prevalence is likely higher in patients referred for RH (eg, up to 4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Symptoms include paroxysmal hypertension (which may be sustained in up to 50% of those with high norepinephrine production or orthostatic in epinephrine-predominant tumors) associated with headache, palpitations, pallor, and piloerection” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Usual blood pressure and vascular mortality: one million adults
“Information was obtained on each of one million adults with no previous vascular disease recorded at baseline in 61 prospective observational studies of blood pressure and mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At ages 40-69 years, each difference of 20 mm Hg usual SBP (or, approximately equivalently, 10 mm Hg usual DBP) is associated with more than a twofold difference in the stroke death rate, and with twofold differences in the death rates from IHD and from other vascular causes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Excess risk in resistant hypertension: guideline statements
Excess risk in resistant hypertension: Kaiser Permanente Southern California cohort
“We sought to compare the risk of end stage renal disease (ESRD), ischemic heart event (IHE), congestive heart failure (CHF), cerebrovascular accident (CVA), and all-cause mortality among 470,386 individuals with resistant and nonresistant hypertension (non-RH).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Resistant hypertension (cRH and uRH) compared to non-RH, had multivariable adjusted hazard ratios (95% confidence intervals) of 1.32 (1.27–1.37), 1.24 (1.20–1.28), 1.46 (1.40–1.52), 1.14 (1.10–1.19), and 1.06 (1.03–1.08) for ESRD, IHE, CHF, CVA, and mortality, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The risk of ESRD and CVA and were 25% and 23% greater, respectively, in uRH compared to cRH supporting the linkage between blood pressure and both outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Excess risk in resistant hypertension: incident treated hypertension cohort
“Following multivariable adjustment including baseline patient demographics, comorbidities, study site, and year of study entry, resistant hypertension was associated with increased risk of adverse CV outcomes (HR 1.47, 95% CI 1.33–1.62, p<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Excess risk in uncontrolled and true resistant hypertension
“Prospective studies using ABPM have suggested an almost 2-fold increased risk of CVD events in patients with true RH compared with those with hypertension responsive to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the REGARDS study (Reasons for Geographic and Racial Differences in Stroke), uncontrolled RH was associated with a 2-fold increased risk of coronary heart disease compared with controlled RH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BP control reduced the risk of incident stroke, coronary heart disease, or heart failure by 13% among those with RH compared with a 31% lower risk of these outcomes among patients without RH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with CKD, RH is associated with higher risk of myocardial infarction, stroke, peripheral arterial disease, heart failure, and all-cause mortality compared with patients without RH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Excess risk in primary aldosteronism
“We identified 31 studies including 3838 patients with primary aldosteronism and 9284 patients with essential hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After a median of 8·8 years (IQR 6·2-10·7) from the diagnosis of hypertension, compared with patients with essential hypertension, patients with primary aldosteronism had an increased risk of stroke (odds ratio [OR] 2·58, 95% CI 1·93-3·45), coronary artery disease (1·77, 1·10-2·83), atrial fibrillation (3·52, 2·06-5·99), and heart failure (2·05, 1·11-3·78).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular risk reduction per 5 mm Hg systolic blood pressure: individual participant data meta-analysis
“Data for 344 716 participants from 48 randomised clinical trials were available for this analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On average, a 5 mm Hg reduction of systolic blood pressure reduced the risk of a major cardiovascular event by about 10%; the corresponding proportional risk reductions for stroke, heart failure, ischaemic heart disease, and cardiovascular death were 13%, 13%, 8%, and 5%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular risk reduction per 10 mm Hg systolic blood pressure: trial-level meta-analysis
“We identified 123 studies with 613,815 participants for the tabular meta-analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Every 10 mm Hg reduction in systolic blood pressure significantly reduced the risk of major cardiovascular disease events (relative risk [RR] 0·80, 95% CI 0·77-0·83), coronary heart disease (0·83, 0·78-0·88), stroke (0·73, 0·68-0·77), and heart failure (0·72, 0·67-0·78), which, in the populations studied, led to a significant 13% reduction in all-cause mortality (0·87, 0·84-0·91).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the effect on renal failure was not significant (0·95, 0·84-1·07).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was no clear evidence that proportional risk reductions in major cardiovascular disease differed by baseline disease history, except for diabetes and chronic kidney disease, for which smaller, but significant, risk reductions were detected.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Burden of hypertension
Humanistic burden and health-related quality of life
Health-related quality of life and SF-6D utility in apparent treatment-resistant hypertension on four or more drug classes: MEPS 2000 to 2011
“We aimed to compare HrQoL measures in adults with apparent TRH (aTRH) and non-resistant hypertension among nationally representative US Medical Expenditure Panel Survey data pooled from 2000 to 2011.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“2501 (4.4%) met criteria for aTRH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Persons with aTRH, compared with non-resistant hypertension, had lower mean PCS scores (35.8 vs 43.2; P<0.0001), and utility (0.68 vs 0.74; P<0.0001), but similar MCS scores (49.1 vs 50.4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In multivariable-adjusted analyses, aTRH was associated with a 2.37 (95% CI 1.71 to 3.02) lower PCS score and 0.02 (95% CI 0.01 to 0.03) lower utility, compared with non-resistant hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, aTRH was associated with substantially lower HrQoL in physical functioning and health utility, but not in mental functioning, compared with non-resistant hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Proposed contributors to lower quality of life in treatment-resistant hypertension: review
“Recent evidence, although limited, suggests that TRH may also adversely affect health-related quality of life (HrQoL) and other patient-reported outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A number of recent studies focusing on both the general hypertensive population and those with TRH suggest that patient awareness of difficult-to-control blood pressure, chronically elevated blood pressure levels, and the use of aggressive medication regimens with attendant cumulative adverse effects may play significant roles.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SF-36 and SF-12 scores in hypertension compared with normotension: meta-analysis of 20 studies
“Most of the 20 studies selected for the systematic review identified lower quality of life in patients with hypertension, but they were very heterogeneous in regard to selection criteria and comparison groups, limiting their external validity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The meta-analysis identified lower scores in hypertensive patients for physical [-2.43; 95% confidence interval (CI) -4.77 to -0.08] and mental (-1.68; 95% CI -2.14 to -1.23) components.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Quality of life of individuals with hypertension is slightly worse than that of normotensive individuals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D index scores for hypertension and its cardiovascular complications: US catalogue from MEPS 2000 to 2002
“The nationally representative Medical Expenditure Panel Survey (MEPS) was pooled (2000−2002) to create a data set of 38,678 adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health state utilities used in the ICER model of aldosterone synthase inhibitors
| Health state | Utility or disutility |
|---|---|
| Hypertension alone | “Age-specific” |
| Acute myocardial infarction, disutility (3 months) | “-0.15” |
| Post-myocardial infarction, disutility | “-0.041” |
| Acute stroke, disutility (3 months) | “-0.19” |
| Post-stroke, disutility | “-0.052” |
| Coronary heart disease, disutility | “-0.034” |
| Heart failure, disutility | “-0.064” |
| End-stage kidney disease, disutility | “-0.170” |
EQ-5D-5L quality of life in 56 participants with resistant hypertension: RHYME-RCT
“A total of 56 patients with median age 61.5 [25th–75th percentile: 55.8–69.3] years (21.4% women) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 12 months, no differences were observed in EQ-5D-5L index (0.81 [0.69–0.89] vs. 0.89 [0.73–1.00]; P = 0.18) and visual analogue scale score on general patient-perceived health (70 [60–80] vs. 70 [60–82]; P = 0.53) between the intervention-arm and the standard-of-care only-arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Irrespective of the intervention, independent positive predictors of the percentage adherence were patient age, EQ-5D-5L index score, BMQ-specific necessity score and concern score, whereas the total number of drugs prescribed was a negative predictor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment burden: patient input on pill burden, copays, and coverage barriers
Pill burden and nonadherence in resistant hypertension: review
“Reasons include adverse drug effects, pill burden, drug costs, long duration of treatment, and lack of communication from clinicians about the importance of medication adherence and persistence” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because adherence declines as the number of medications rises and the treatment regimen becomes more complex, poor adherence is a particular problem complicating the treatment of patients with RHT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of prescribed antihypertensive drugs and biochemically confirmed nonadherence in 1348 participants
“We used high-performance liquid chromatography-tandem mass spectrometry of urine and serum to detect nonadherence and explored its association with the main demographic- and therapy-related factors in 1348 patients with hypertension from 2 European countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The rates of nonadherence to antihypertensive treatment were 41.6% and 31.5% in the UK and Czech populations, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Each increase in the number of antihypertensive medications led to 85% and 77% increase in nonadherence (P<0.001) in the UK and Czech populations, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We demonstrate that the number and class of prescribed antihypertensives are modifiable risk factors for biochemically confirmed nonadherence to blood pressure-lowering therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of medication nonadherence in apparent treatment-resistant hypertension: meta-analysis of 24 studies
“From an initial discovery of 921 studies, we identified 24 studies that measured medication adherence for patients with uncontrolled BP despite being prescribed three or more antihypertensive medications of different classes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“By using a random effects model, the pooled prevalence of nonadherence was 31.2% (95% confidence interval = 20.2-44.7, I = 99.50) with nonadherence rates ranging from 3.3 to 86.1%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Findings indicate that medication nonadherence is a significant problem among aTRH patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Regimen simplification: single-pill compared with free-equivalent combination therapy, systematic review of 44 studies
“Following screening, 44 studies were included. The majority (18 of 23) of studies measuring adherence showed adherence was significantly improved in patients receiving SPCs versus FECs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SPC therapy leads to improved adherence and persistence compared with FEC therapy and may lead to better BP control in patients with hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
National health care expenditures and events associated with hypertension: MEPS 2019
“Hypertension was associated with $2,759 (95% confidence interval [CI]: $2,039, $3,479) in health care expenditures and 10.3 (95% CI: 9.3, 11.3) health care events, including prescriptions filled, in 2019 per person.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Estimated annual national health care expenditures associated with hypertension were about $219.2 billion in the United States in 2019. This includes $32.5 billion in prescribed medication purchases, $70.2 billion in outpatient services, and $79.4 billion in inpatient services. The number of health care events associated with hypertension was about 817.4 million, including 538.2 million prescribed medication purchases, 168.1 million outpatient visits, 3.5 million inpatient visits, and 6.0 million ED visits” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results from this study indicated that hypertension was associated with more than 10% of the total health care expenditures and events at national level” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual costs of high blood pressure: CDC
Incremental expenditure for adults with hypertension: MEPS 2003 to 2014
“Relative to individuals without hypertension, individuals with hypertension had $1920 higher annual adjusted incremental expenditure, 2.5 times the inpatient cost, almost double the outpatient cost, and nearly triple the prescription medication expenditure. Based on the prevalence of hypertension in the United States, the estimated adjusted annual incremental cost is $131 billion per year higher for the hypertensive adult population compared with the nonhypertensive population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Direct and indirect cost and hospital, office, and emergency department use: AHA statistics
“The estimated direct and indirect cost of HBP for 2020 to 2021 (annual average) was $49.0 billion” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Estimated US health care expenditures for hypertension in 2016 were $79 (95% CI, $72.6–$86.8) billion. Of 154 health conditions, hypertension ranked 10th in health care expenditures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From 2011 to 2021, the number of inpatient discharges from short-stay hospitals with HBP as the principal diagnosis increased from 296 253 to 1 311 528. The number of discharges with any listing of HBP increased from 16 112 764 to 17 160 070 in that same time period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 2019, 56 795 000 of 1 036 484 000 physician office visits had a primary diagnosis of essential hypertension” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 779 438 ED discharges with a principal diagnosis of essential hypertension in 2021” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US spending on treatment of hypertension by type of care and payer, 2019
| Measure | Treatment of hypertension |
|---|---|
| Total 2019 spending, US$ billions (95% CI) | “35.57 (34.9-36.2)”View highlighted excerpt for this quote |
| Share of spending in adults older than 65 years, % | “56.7”View highlighted excerpt for this quote |
| Inpatient care, % | “0.3”View highlighted excerpt for this quote |
| Emergency department, % | “4.5”View highlighted excerpt for this quote |
| Ambulatory care, % | “41.8”View highlighted excerpt for this quote |
| Prescribed retail pharmaceuticals, % | “39.5”View highlighted excerpt for this quote |
| Nursing facility, % | “4.0”View highlighted excerpt for this quote |
| Medicare, % | “39.9”View highlighted excerpt for this quote |
| Medicaid, % | “14.3”View highlighted excerpt for this quote |
| Private insurance, % | “29.3”View highlighted excerpt for this quote |
| Out of pocket, % | “16.6”View highlighted excerpt for this quote |
Resource use and costs with uncontrolled compared with controlled blood pressure in apparent treatment-resistant hypertension and stage 3 or 4 CKD: US claims, 3966 patients
“This retrospective cohort study used linked IQVIA Ambulatory EMR–US and IQVIA PharMetrics Plus claims databases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 3,966 patients with stage 3–4 CKD using ≥3 antihypertensive medications, 2,479 had uncontrolled BP and 1,487 had controlled BP. After adjusting for baseline differences, patients with uncontrolled vs. controlled BP had a higher risk of MACE+ (HR [95% CI]: 1.18 [1.03–1.36]), ESRD (1.85 [1.44–2.39]), inpatient hospitalization (rate ratio [95% CI]: 1.35 [1.28–1.43]), and outpatient visits (1.12 [1.11–1.12]) and incurred higher total medical and pharmacy costs (mean difference [95% CI]: $10,055 [$6,741–$13,646] per patient per year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total medical costs were driven primarily by outpatient visits (+$6,514) and inpatient hospital admissions (+$3,202).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, in our sensitivity analysis using a BP threshold of ≥140/90 mm Hg, there were increases in inpatient hospitalizations (HR, 1.26) and outpatient visits (HR, 1.18), and total costs increased by approximately $9,000.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outpatient visit frequency in apparent treatment-resistant hypertension: REGARDS linked with Medicare claims
“We studied the frequency and intensity of care for aTRH among participants aged 65 years and older in the US-based REGARDS study linked with Medicare claims.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 4650 participants with hypertension, 468 (10.1%) had UaTRH, 247 (5.3%) had CaTRH, and 3935 (84.6%) had hypertension but did not have aTRH. For hypertension-related visits, those with UaTRH saw primary care physicians and cardiologists more frequently than those without aTRH (mean primary care visits per year: 2.77 vs 2.27, P < .001; cardiologists: 0.50 vs 0.35, P = .014).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many people with UaTRH are not seen more than once per year for hypertension and may benefit from increased care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Added expenditure attributed to apparent resistant hypertension: review
“Compared with nonresistant hypertension, RHT is associated with an added economic burden on both the US health care system and individual patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Apparent RHT is estimated to increase US health care expenditures by $11 billion to $18 billion per year over those associated with non-resistant hypertension” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Suboptimal adherence to prescribed medications also increases total health care costs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual costs of cardiovascular health states used in the ICER model, 2025 US dollars
| Health state | Direct medical cost | Productivity cost (modified societal perspective) |
|---|---|---|
| Hypertension (annual) | “$3,211” | Not reported |
| Stroke (acute and annual; annual for productivity) | “$20,442 / $20,697” | “$16,781” |
| Myocardial infarction (acute and annual; annual for productivity) | “$25,832 / $17,106” | “$19,028” |
| Coronary heart disease (annual) | “$13,798” | “$7,092” |
| Heart failure (index hospitalization and annual; annual for productivity) | “$16,671 / $33,890” | “$16,004” |
| End-stage kidney disease (annual) | “$108,953” | “$17,650” |
Productivity loss associated with hypertension in the United States: review of 27 studies
“Twenty-seven articles met the inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Annual absenteeism was estimated to cost more than $11 billion, nationally controlling for sociodemographic characteristics. The annual additional costs per person were estimated at $63 for short-term disability, $72–$330 for absenteeism, and $53–$156 for presenteeism, controlling for participant characteristics; and may be as high as $2362 for absenteeism and presenteeism when considered in combination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The annual additional time loss per person was estimated as 1.3 days for absenteeism, controlling for common hypertension comorbidities, including stroke and diabetes; and 15.6 days for work and home productivity loss combined, controlling for sociodemographic characteristics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The loss from absenteeism alone might be more than 20% of the total medical expenditure of hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antihypertensive adherence, medical costs, and disability costs in commercially insured adults: MarketScan 2019
“We conducted cross‐sectional analyses using MarketScan databases, which included individuals aged 18 to 64 years with noncapitated health insurance plans in 2019.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“54.4% adhered to antihypertensives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Per person, antihypertensive medication adherence was associated with $1441 lower total medical costs, $11 lower sick absence costs, $291 lower short‐term disability costs, and $69 lower long‐term disability costs. Per 1000 individuals, medication adherence was associated with lower health care use, including 200 fewer emergency department visits and 90 fewer inpatient admissions, and productivity‐related outcomes, including 20 fewer sick absence days and 442 fewer short‐term disability days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Projected health care costs of cardiovascular risk factors including hypertension through 2050
“We used nationally representative health, economic, and demographic data to project health care costs attributable to key cardiovascular risk factors (hypertension, diabetes, hypercholesterolemia) and conditions (coronary heart disease, stroke, heart failure, atrial fibrillation) through 2050.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Annual inflation-adjusted (2022 US dollars) health care costs of cardiovascular risk factors are projected to triple between 2020 and 2050, from $400 billion to $1344 billion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of hypertension on families
Out-of-pocket share of US spending on treatment of hypertension, 2019
| Payer | Share of 2019 spending on treatment of hypertension, % |
|---|---|
| Medicare | “39.9”View highlighted excerpt for this quote |
| Medicaid | “14.3”View highlighted excerpt for this quote |
| Private insurance | “29.3”View highlighted excerpt for this quote |
| Out of pocket | “16.6”View highlighted excerpt for this quote |
Cost-related medication nonadherence among US adults with hypertension: National Health Interview Survey 2017
“Participants with self-reported hypertension from the 2017 National Health Interview Survey were included (n = 7,498).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 10.7% reported CRMN, 83.6% reported current antihypertensive medication use, and 67.4% reported normal blood pressure within past 12 months. Adjusted percentages of current antihypertensive medication use (88.6% vs. 82.9%, P < 0.001) and self-reported normal blood pressure (69.8% vs. 59.5%, P = 0.002) were higher among those without CRMN compared with those with CRMN.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Financial barriers to medication adherence persist and impact hypertension management.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-related medication nonadherence by age, sex, and insurance status: National Health Interview Survey 2019 to 2022
“This analytical cross-sectional study utilized data from the National Health Interview Survey Sample from 2019 to 2022.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Women aged 18-64 years more likely (adjusted odds ratio (aOR) 1.44; 95% CI 1.18, 1.75) to experience CRN than men. Notably, uninsured individuals in both the 18-64 (aOR 2.21; 95% CI 1.51, 3.25) and ≥ 65 (aOR 5.55; 95% CI 1.36, 22.75) age groups were at increased risk of facing CRN.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“To mitigate CRN, health quality strategies like prescribing generics, connecting patients with assistance programs, and implementing policies to reduce out-of-pocket costs are essential.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Additive copays for multiple medications: patient input
Caregiver time and cost burden in uncontrolled or resistant hypertension
No evidence found.
Economic impact of diagnostic testing
Screening for primary aldosteronism with aldosterone and renin: Endocrine Society guideline
“We suggest that all individuals with hypertension be screened for PA by measuring aldosterone and renin and determining the aldosterone to renin ratio, and that subsequent clinical care be guided by the results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The GDP used the GRADE Evidence to Decision (EtD) framework to consider contextual factors, such as stakeholder values and preferences, costs and required resources, cost-effectiveness, acceptability, feasibility, and the potential impact on health equity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost and testing burden of broader primary aldosteronism screening: 2025 AHA/ACC guideline
Primary aldosteronism testing rates and treatment in 269 010 Veterans with apparent treatment-resistant hypertension
“Veterans with apparent treatment-resistant hypertension (n = 269 010) from 2000 to 2017” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“4277 (1.6%) patients who were tested for primary aldosteronism were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Testing was associated with a 4-fold higher likelihood of initiating MRA therapy (HR, 4.10 [CI, 3.68 to 4.55]) and with better BP control over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Testing for primary aldosteronism in patients with apparent treatment-resistant hypertension is cost-effective and may substantially improve long-term outcomes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Underdiagnosis, downstream costs, and cost-effectiveness of broader screening: review
“Fewer than 2% of eligible patients are screened for primary aldosteronism (PA) despite evidence that early detection and targeted therapy are associated with lower cardiovascular and kidney morbidity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The resulting underdiagnosis not only prolongs exposure to excess aldosterone but also increases healthcare utilization and costs through preventable hospitalizations, procedural interventions, and long-term management of aldosterone-mediated end-organ damage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a modeling study focused on patients with apparent treatment resistant hypertension in the U.S., Gaziano et al. assessed the cost-effectiveness of multiple diagnostic strategies and an empiric MRA treatment approach. Screening with ARR followed by confirmatory testing, AVS, and surgical adrenalectomy, when appropriate, were cost-effective, with incremental cost-effectiveness ratios well within commonly accepted thresholds.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of primary aldosteronism screening and subtype diagnosis in resistant hypertension: US decision model
“At a U.S. WTP threshold of $150,000/QALY and without adjustments in HRQoL for patients with surgically untreated PA, CT/AVS strategy is the cost-effective choice with an ICER of $82,000/QALY” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ICERs for CT alone and AVS alone were $200,000/QALY and $492,000/QALY; the other strategies were more costly and less effective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Integrating differential patient-reported health-related quality of life adjustments for patients with PA, ICERs for screening patients with CT followed by AVS, CT alone, and AVS alone were $52,000/QALY, $114,000/QALY, and $269,000/QALY gained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CT scanning followed by AVS was a cost-effective strategy to screen for PA among patients with resistant hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Test or procedure (CPT or DRG codes as printed) | Base-case cost |
|---|---|
| Screening aldosterone to renin ratio (CPT 82088, 84244, 84132) | “$93”View highlighted excerpt for this quote |
| Confirmatory saline infusion testing (CPT 96365, 93666) | “$141”View highlighted excerpt for this quote |
| Abdominal CT (CPT 74170) | “$329”View highlighted excerpt for this quote |
| Adrenal venous sampling (CPT 75893, 36500) | “$2,645”View highlighted excerpt for this quote |
| Adrenalectomy, surgery and anesthesia (CPT 60650, 00866) | “$3,054”View highlighted excerpt for this quote |
| One year cost of spironolactone | “$158”View highlighted excerpt for this quote |
Medicare fee schedule costs of primary aldosteronism work-up and therapeutic drug monitoring-guided screening in resistant hypertension
“Cost of therapeutic drug monitoring for three drugs=3×$25=$75” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cost of screening for primary aldosteronism (PA)=$30 for plasma renin activity+$56 for serum aldosterone=$86” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cost of adrenal vein sampling=$2328.73” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cost of computed tomographic scan of adrenal glands=$588.53” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A retrospective analysis from a hypertension referral clinic showed that prevalence of PA in adherent patients with TRH by TDM was significantly higher than in nonadherent patients (28% vs 8%, P<.05). Furthermore, cost analysis showed that TDM‐guided PA screening was $590.69 less expensive per patient, with minimal impact on the diagnostic accuracy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of primary aldosteronism screening in all adults with hypertension from age 40: Australian Markov model
“A Markov model was used to estimate the cost-effectiveness of screening for primary aldosteronism in treatment and disease (cardiovascular disease and stroke) naive hypertensive patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The results from this study demonstrated that screening all hypertensive patients for primary aldosteronism from age 40 is cost-effective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Care-pathway cost of investigating secondary and apparent treatment-resistant hypertension in a specialist clinic: Ireland
“Sixty-five patients originally recruited for a study of medication adherence in hypertension were included in the sample.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The total care-pathway cost per patient, taking into account clinic visits, clinical reviews, investigations and MDT discussion, was estimated to be €3277, on average. For the patient subgroups, the average cost was €5644 for patients diagnosed with primary aldosteronism and €1446 for patients diagnosed with essential hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare coverage of ambulatory blood pressure monitoring
Cost-effectiveness of clinic, home, and ambulatory blood pressure measurement for diagnosis: US model
“We compared quality-adjusted life-years and lifetime costs ($US 2017 from the US healthcare perspective) associated with clinic BP measurement, home BP monitoring, and ABPM under 2 scenarios: positive and negative initial screen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the screen-positive scenario, ABPM was the dominant strategy among all age and sex groups. Compared with clinic BP measurement, ABPM was associated with cost-savings ranging from $77 (women 80 years of age) to $5013 (women 21 years of age).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ABPM is recommended as the diagnostic strategy of choice for most adults in primary care settings regardless of initial screening results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Practicality and availability of home and ambulatory blood pressure monitoring: 2025 AHA/ACC guideline
Costs and cost-effectiveness of self-measured blood pressure monitoring: Community Guide systematic review of 22 studies
“The literature search from database inception to March 2015 identified 22 studies for inclusion with three types of interventions: SMBP used alone, SMBP with additional support, and SMBP within team-based care (TBC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median costs of intervention were $60 and $174 per person for SMBP alone and SMBP with additional support, respectively, and $732 per person per year for SMBP within TBC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SMBP monitoring interventions with additional support or within TBC are cost effective. Cost effectiveness of SMBP used alone could not be determined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Lifestyle and dietary interventions
Lifestyle recommendation for all adults: 2025 AHA/ACC guideline
Expected blood pressure reductions by intervention: 2025 AHA/ACC guideline
Potassium-based salt substitutes: 2025 AHA/ACC guideline
Sodium target and lifestyle intervention in resistant hypertension: 2024 ESC guideline
Diet and exercise program in resistant hypertension: TRIUMPH randomized trial
“One hundred forty patients with RH (mean age 63 years; 48% female; 59% Black; 31% with diabetes; 21% with chronic kidney disease) were randomly assigned to a 4-month program of lifestyle modification (C-LIFE) including dietary counseling, behavioral weight management, and exercise; or a single counseling session providing standardized education and physician advice (SEPA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Between-group comparisons revealed that the reduction in clinic SBP was greater in C-LIFE (−12.5 [95% CI: −14.9, −10.2] mm Hg) compared with SEPA” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“24-hour ambulatory SBP also was reduced in C-LIFE (−7.0 [95% CI: −8.5, −4.0] mm Hg), with no change in SEPA (−0.3 [95% CI: −4.0, 3.4] mm Hg) (P = .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dietary sodium restriction in resistant hypertension: crossover trial
“Twelve subjects with resistant hypertension entered into a randomized, cross-over evaluation of low (50 mmol/24-hr × 7 days) and high sodium diets (250 mmol/24-hr × 7 days) separated by a 2-week washout period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Low- compared to high-salt diet decreased office systolic and diastolic blood pressure by 22.7 and 9.1 mm Hg, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sodium reduction combined with the DASH diet: DASH-Sodium trial
“A total of 412 participants were randomly assigned to eat either a control diet typical of intake in the United States or the DASH diet.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As compared with the control diet with a high sodium level, the DASH diet with a low sodium level led to a mean systolic blood pressure that was 7.1 mm Hg lower in participants without hypertension, and 11.5 mm Hg lower in participants with hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Thiazide-type diuretics, Renin-Angiotensin system inhibitors, and calcium channel blockers
First-line drug classes: 2025 AHA/ACC guideline
Initial combination therapy and single-pill combinations: 2025 AHA/ACC guideline
Three-drug regimen before a diagnosis of resistant hypertension: 2025 AHA/ACC guideline
Chlorthalidone and hydrochlorothiazide: 2025 AHA/ACC guideline
First-line drug classes and triple combination: 2024 ESC guideline
Chlorthalidone in stage 4 chronic kidney disease: CLICK trial
“A total of 160 patients underwent randomization, of whom 121 (76%) had diabetes mellitus and 96 (60%) were receiving loop diuretics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The adjusted change in 24-hour systolic blood pressure from baseline to 12 weeks was −11.0 mm Hg (95% confidence interval [CI], −13.9 to −8.1) in the chlorthalidone group and −0.5 mm Hg (95% CI, −3.5 to 2.5) in the placebo group. The between-group difference was −10.5 mm Hg (95% CI, −14.6 to −6.4) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hypokalemia, reversible increases in serum creatinine level, hyperglycemia, dizziness, and hyperuricemia occurred more frequently in the chlorthalidone group than in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Steroidal mineralocorticoid receptor antagonists
Spironolactone as the fourth drug: 2025 AHA/ACC guideline
Eplerenone as an alternative: 2025 AHA/ACC guideline
Aldosterone antagonist dosing and cautions: 2025 AHA/ACC guideline drug table
Spironolactone and eplerenone in resistant hypertension: 2024 ESC guideline
Spironolactone as fourth-line treatment: 2023 ESH guideline
Spironolactone versus placebo, bisoprolol, and doxazosin: PATHWAY-2 trial
“Patients rotated, in a preassigned, randomised order, through 12 weeks of once daily treatment with each of spironolactone (25–50 mg), bisoprolol (5–10 mg), doxazosin modified release (4–8 mg), and placebo, in addition to their baseline blood pressure drugs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average reduction in home systolic blood pressure by spironolactone was superior to placebo (–8·70 mm Hg [95% CI −9·72 to −7·69]; p<0·0001), superior to the mean of the other two active treatments (doxazosin and bisoprolol; −4·26 [–5·13 to −3·38]; p<0·0001), and superior when compared with the individual treatments; versus doxazosin (–4·03 [–5·04 to −3·02]; p<0·0001) and versus bisoprolol (–4·48 [–5·50 to −3·46]; p<0·0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“58% of patients had their blood pressure controlled with spironolactone, which was superior to rates for other treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Spironolactone safety and population limits: PATHWAY-2 trial
“Notably, discontinuations due to renal impairment, hyperkalaemia, and gynaecomastia were not increased with spironolactone relative to other treatments and placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only six (2%) of 285 patients exposed to spironolactone developed a serum potassium on a single occasion greater than 6·0 mmol/L, with a maximum of 6·5 mmol/L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our study excluded patients with an eGFR less than 45 mL/min, as have previous studies, thus there are no data on the safety profile of spironolactone in patients with resistant hypertension and an eGFR less than 45 mL/min.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aldosterone antagonists versus beta-blockers as fourth agents: claims cohort
“We identified 80 598 patients with RH (mean age: 61 years, 51% males), of which 6626 initiated AA and 73 972 initiated BB as the fourth antihypertensive agent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with RH, initiation of AA as a fourth-line antihypertensive agent did not significantly reduce major adverse cardiovascular event risk relative to BB initiation (aHR, 0.77 [95% CI, 0.50-1.19]) but did substantially increase the risk of hyperkalemia (aHR, 3.86 [95% CI, 2.78-5.34]), gynecomastia (aHR, 9.51 [95% CI, 5.69-15.89]), and kidney function deterioration (aHR, 1.63 [95% CI, 1.34-1.99]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Spironolactone prescribing information: hypertension indication and dosing
Spironolactone prescribing information: hyperkalemia and gynecomastia
Eplerenone prescribing information: hypertension indication, dosing, and contraindications
Comparators for aldosterone synthase inhibitors and hyperkalemia rates: ICER evidence report
Epithelial sodium channel blockers
Amiloride when mineralocorticoid receptor antagonists are not tolerated: 2025 AHA/ACC guideline
Amiloride as an alternative to spironolactone: 2024 ESC guideline
Amiloride dosing and availability: 2023 ESH guideline
Amiloride open-label runout: PATHWAY-2 mechanisms substudy
“assessed the effect of amiloride 10–20 mg once daily on clinic systolic blood pressure during an optional 6–12 week open-label runout phase (substudy 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Amiloride (10 mg once daily) reduced clinic systolic blood pressure by 20·4 mm Hg (95% CI 18·3–22·5), compared with a reduction of 18·3 mm Hg (16·2–20·5) with spironolactone (25 mg once daily). No serious adverse events were recorded, and adverse symptoms were not systematically recorded after the end of the double-blind treatment. Mean plasma potassium concentrations increased from 4·02 mmol/L (95% CI 3·95–4·08) on placebo to 4·50 (4·44–4·57) on amiloride (p<0·0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Amiloride versus spironolactone: randomized noninferiority trial
“Prospective, open-label, blinded end-point randomized clinical trial conducted at 14 sites in South Korea. From November 16, 2020, to February 29, 2024, 118 patients with home SBP of 130 mm Hg or greater after a 4-week run-in period with a fixed-dose triple medication combination (angiotensin receptor blocker, calcium channel blocker, and thiazide) were enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were randomized in a 1:1 ratio to receive 12.5 mg/d of spironolactone (n = 60) or 5 mg/d of amiloride (n = 58). If home SBP remained 130 mm Hg or greater and serum potassium was less than 5.0 mmol/L after 4 weeks, dosages were increased to 25 mg/d and 10 mg/d, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 12, mean home SBP measurements were changed from baseline by −13.6 (SD, 8.6) mm Hg and −14.7 (SD, 11.0) mm Hg in the amiloride and spironolactone groups, respectively (between-group difference in change, −0.68 mm Hg; 90% CI, −3.50 to 2.14 mm Hg), with amiloride demonstrating noninferiority to spironolactone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Amiloride trial limitations: dose and kidney function
“First, we did not compare the efficacy of higher doses of spironolactone (50 mg vs 20 mg), as used in the PATHWAY-2 trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, we excluded participants with an estimated glomerular filtration rate of less than 50 mL/min/1.73 m2; hence, our results may not be generalizable to patients with chronic kidney disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aldosterone synthase inhibitors
Class: a new mechanism developed to treat hypertension
Baxdrostat (BAXFENDY): the first approved aldosterone synthase inhibitor
Baxdrostat: BaxHTN, uncontrolled or resistant hypertension
“This multinational, randomized, double-blind, placebo-controlled phase 3 trial recruited participants with seated office systolic blood pressure (seated-SBP) ≥140 mmHg and <170 mmHg, despite stable treatment with 2 (uncontrolled hypertension) or ≥3 (resistant hypertension) antihypertensive medications, including a diuretic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 12, change from baseline in least-squares mean seated-SBP for baxdrostat 1mg was –14.5 mmHg (95% confidence interval [CI], –16.5 to –12.5); baxdrostat 2mg, –15.7 mmHg (–17.6 to –13.7); versus placebo, –5.8 mmHg (–7.9 to –3.8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baxdrostat: Bax24, resistant hypertension
“Following a 2-week placebo run-in period, patients with 24 h ambulatory SBP ≥130 mm Hg were randomly assigned (1:1) to receive 2 mg baxdrostat or placebo orally once daily for 12 weeks, in addition to background therapy (stratified by baseline ambulatory SBP <140 mm Hg or ≥140 mm Hg).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Baxdrostat significantly reduced 24 h ambulatory SBP versus placebo in patients with resistant hypertension, providing further evidence of the potential of aldosterone synthase inhibition for treatment of hard-to-control hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baxdrostat: chronic kidney disease with uncontrolled hypertension
Lorundrostat: investigational aldosterone synthase inhibitor under FDA review
Vicadrostat: investigational, without a hypertension trial in its phase 3 set
Class effect on blood pressure and electrolytes across randomized trials
“ASI reduced systolic blood pressure (SBP) (MD: –6.7 mm Hg; CrI: −8.78, −4.59; τ2 3.24), diastolic blood pressure (MD: -2.09 mm Hg; CrI: −3.68, −0.44; τ2 1.44), and hypertensive urgency (OR: 0.36; CrI: 0.13, 0.90; τ2 0.07) compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second-generation ASIs had a high likelihood of a clinically significant reduction in SBP compared with placebo. However, hyperkalemia, hyponatremia, and hypotension were more frequent with ASIs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term follow-up available for the class
Endothelin receptor antagonists
Aprocitentan: mechanism of action
Aprocitentan (TRYVIO): indication, dosage, and boxed warning
Aprocitentan: PRECISION trial in resistant hypertension
“Patients were eligible for randomisation if their sitting systolic blood pressure was 140 mm Hg or higher despite taking standardised background therapy consisting of three antihypertensive drugs, including a diuretic.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The least square mean (SE) change in office systolic blood pressure at 4 weeks was -15·3 (SE 0·9) mm Hg for aprocitentan 12·5 mg, -15·2 (0·9) mm Hg for aprocitentan 25 mg, and -11·5 (0·9) mm Hg for placebo, for a difference versus placebo of -3·8 (1·3) mm Hg (97·5% CI -6·8 to -0·8, p=0·0042) and -3·7 (1·3) mm Hg (-6·7 to -0·8; p=0·0046), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The respective difference for 24 h ambulatory systolic blood pressure was -4·2 mm Hg (95% CI -6·2 to -2·1) and -5·9 mm Hg (-7·9 to -3·8).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After 4 weeks of withdrawal, office systolic blood pressure significantly increased with placebo versus aprocitentan (5·8 mm Hg, 95% CI 3·7 to 7·9, p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent adverse event was mild-to-moderate oedema or fluid retention, occurring in 9%, 18%, and 2% for patients receiving aprocitentan 12·5 mg, 25 mg, and placebo, during the 4-week double-blind part, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aprocitentan: onset of effect and dose in the prescribing information
Aprocitentan: position in the 2025 AHA/ACC guideline
Aprocitentan: REMS removed in April 2025
Aprocitentan: commercial availability and specialist-focused launch
Beta-blockers, alpha-blockers, central sympatholytics, and direct vasodilators
Fourth- and fifth-line alternatives: 2025 AHA/ACC guideline
Beta-blockers as secondary agents: 2025 AHA/ACC guideline
Alpha-1 blockers, central agents, and direct vasodilators: 2025 AHA/ACC guideline drug table
Order of alternative agents: 2024 ESC guideline
Alternatives when mineralocorticoid receptor antagonists are not tolerated: 2023 ESH guideline
Spironolactone versus clonidine as the fourth drug: ReHOT trial
“Patients with resistant hypertension (no office and ambulatory blood pressure [BP] monitoring control, despite treatment with 3 drugs, including a diuretic, for 12 weeks) were randomized to an additional 12-week treatment with spironolactone (12.5-50 mg QD) or clonidine (0.1-0.3 mg BID).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Renal denervation
FDA approval: Symplicity Spyral radiofrequency system
FDA approval: Paradise ultrasound system
Medicare coverage with evidence development: CMS national coverage decision
CMS assessment of the evidence
Place of renal denervation in resistant hypertension: 2025 AHA/ACC guideline
Patient selection for renal denervation: 2025 AHA/ACC guideline
Renal denervation recommendation and limitations: 2024 ESC guideline
Renal denervation as an additive or alternative option: 2023 ESH guideline
Ultrasound renal denervation in resistant hypertension: RADIANCE-HTN TRIO trial
“Eligible patients were switched to a once daily, fixed-dose, single-pill combination of a calcium channel blocker, an angiotensin receptor blocker, and a thiazide diuretic.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between March 11, 2016, and March 13, 2020, 989 participants were enrolled and 136 were randomly assigned to renal denervation (n=69) or a sham procedure (n=67).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Renal denervation reduced daytime ambulatory systolic blood pressure more than the sham procedure (-8·0 mm Hg [IQR -16·4 to 0·0] vs -3·0 mm Hg [-10·3 to 1·8]; median between-group difference -4·5 mm Hg [95% CI -8·5 to -0·3]; adjusted p=0·022)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ultrasound renal denervation without medications: RADIANCE II trial
“Among 1038 eligible patients, 150 were randomized to ultrasound renal denervation and 74 to a sham procedure (mean age, 55 years [SD, 9.3 years]; 28.6% female; and 16.1% self-identified as Black or African American). The reduction in daytime ambulatory SBP was greater with ultrasound renal denervation (mean, −7.9 mm Hg [SD, 11.6 mm Hg]) vs the sham procedure (mean, −1.8 mm Hg [SD, 9.5 mm Hg]) (baseline-adjusted between-group difference, −6.3 mm Hg [95% CI, −9.3 to −3.2 mm Hg], P < .001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No major adverse events were reported in either group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Radiofrequency renal denervation with medications at 6 months: SPYRAL HTN-ON MED trial
“The treatment difference in the mean 24-hour ambulatory systolic BP from baseline to 6 months between the RDN group (n = 206; -6.5 ± 10.7 mm Hg) and sham control group (n = 131; -4.5 ± 10.3 mm Hg) was -1.9 mm Hg (95% CI: -4.4 to 0.5 mm Hg; P = 0.12).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“RDN was associated with a reduction in office systolic BP compared with sham control at 6 months (adjusted treatment difference: -4.9 mm Hg; P = 0.0015).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Radiofrequency renal denervation with medications at 24 months: SPYRAL HTN-ON MED trial
“At 24 months, the RDN group experienced significantly greater mean reductions in ambulatory systolic BP (−12.1±15.3 mm Hg [n=176] versus −7.0±13.1 mm Hg [n=33]; difference: −5.7 mm Hg; P=0.039) and office systolic BP (−17.4±16.1 mm Hg [n=187] versus −9.0±19.4 mm Hg [n=35]; difference: −8.7 mm Hg; P=0.0034) compared with sham controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinically adverse events were rare, with no instances of renal artery stenosis through 24 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Radiofrequency renal denervation with medications at 36 months: SPYRAL HTN-ON MED pilot cohort
“At 36 months, the ambulatory systolic blood pressure reduction was -18·7 mm Hg (SD 12·4) for the renal denervation group (n=30) and -8·6 mm Hg (14·6) for the sham control group (n=32; adjusted treatment difference -10·0 mm Hg, 95% CI -16·6 to -3·3; p=0·0039).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
- Blood pressure control: In NHANES data from August 2021 to August 2023, 20.7% of US adults with hypertension had blood pressure controlled to less than 130/80 mm Hg, with no significant change from 2017 to March 2020 (22.2%). In a separate NHANES analysis, the age-adjusted proportion with controlled blood pressure declined from 53.8% in 2013 to 2014 to 43.7% in 2017 to 2018. ICER states that more than 70% of adults with hypertension remain above goal and names clinical inertia, pill burden, additive copays, variable tolerance of side effects, and low awareness as contributors.
- Underuse of aldosterone-targeted therapy: Among NHANES adults with apparent treatment-resistant hypertension, 8.3% were taking a mineralocorticoid receptor antagonist, rising from 6.3% in 2003 to 2004 to 13.3% in 2017 to 2020. Among US Veterans with apparent treatment-resistant hypertension, 4,277 (1.6%) were tested for primary aldosteronism, and testing was associated with a 4-fold higher likelihood of starting a mineralocorticoid receptor antagonist (hazard ratio 4.10).
- Tolerability of fourth-line options: The 2025 AHA/ACC guideline states that 4% to 40% of adults with resistant hypertension cannot tolerate spironolactone because of hyperkalemia or antiandrogenic side effects, and that randomized trials have not demonstrated a reduction in home or 24-hour blood pressure with eplerenone at 25 to 100 mg daily compared with placebo. ICER reports gynecomastia rates of 3.9% to 6% with spironolactone in observational hypertension studies. Patient groups told ICER that clinicians are often reluctant to start spironolactone because of potential side effects. With baxdrostat, hyperkalemia led to discontinuation in 5.7% of participants in the BaxHTN long-term extension (safety data to 54 weeks), and serum potassium above 6 mmol/L occurred in 9.5% of the pooled baxdrostat arm and 0.8% of the placebo arm. Edema or fluid retention occurred in 9% of participants receiving aprocitentan at the approved 12.5 mg dose and 2% receiving placebo. ICER describes beta-blockers, alpha blockers, and central sympatholytic drugs as less efficacious and less well tolerated, and the guideline reserves renal denervation for adults with intolerable side effects to optimal drug regimens.
- Adherence and discontinuation: The weighted national nonadherence rate among 23.8 million adults with hypertension who filled antihypertensive prescriptions was 31.0%. A meta-analysis of 24 studies in apparent treatment-resistant hypertension estimated a pooled nonadherence prevalence of 31.2% (range 3.3% to 86.1%). Among Medicare beneficiaries starting antihypertensive treatment, discontinuation was 21.0% in 2007 and 21.3% in 2012, and low adherence fell from 37.4% in 2007 to 31.7% in 2012.
- Therapeutic inertia and access: ICER reports hearing that it often takes three to six months to adjust or add a medication in people with uncontrolled hypertension, and patients described readings above 140 mm Hg that were not acted on. The guideline links clinical inertia, among other factors, to the higher frequency of resistant hypertension in Black populations. Patients told ICER that prior authorization and step therapy can lead people to abandon treatment.
Blood pressure control: NHANES August 2021 to August 2023
Blood pressure control: trends from 1999 to 2018
“the age-adjusted estimated proportion with controlled blood pressure increased from 31.8% in 1999-2000 to 48.5% in 2007-2008, remained stable through 2013-2014 (53.8%), and then declined to 43.7% in 2017-2018.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure control and barriers to treatment: ICER assessment
Underuse of mineralocorticoid receptor antagonists in apparent treatment-resistant hypertension
“Among those with aTRH, 84.3% were on ACE inhibitors/ARBs, 72.1% on thiazide diuretics, 55.4% on calcium channel blockers, 32.3% on a loop diuretic and 8.3% on mineralocorticoid receptor antagonists (MRA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among adults with aTRH, utilization of MRAs increased over time from 6.3% in 2003–2004 to 13.3% in 2017–2020.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“less than 1 in 5 adults with aTRH were prescribed an MRA despite high quality evidence supporting its use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limited adaption could be related to the above issues or concerns specific to MRA use such as hyperkalemia, the need for routine monitoring of labs or concerns about renal dysfunction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Underuse of aldosterone-targeted therapy: lorundrostat phase 3 trial report
“However, aldosterone-targeted antihypertensive medication is underused worldwide in the treatment of hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, MRAs are underused due to safety concerns with hyperkalemia and, in the case of spironolactone, chemotype-specific androgenic effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary aldosteronism testing and mineralocorticoid receptor antagonist initiation
“4277 (1.6%) patients who were tested for primary aldosteronism were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Testing was associated with a 4-fold higher likelihood of initiating MRA therapy (HR, 4.10 [CI, 3.68 to 4.55]) and with better BP control over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Spironolactone and eplerenone intolerance and efficacy: guideline
Hyperkalemia and gynecomastia with mineralocorticoid receptor antagonists
Clinician reluctance to start spironolactone: patient and clinician input to ICER
Aldosterone synthase inhibitors: hyperkalemia with baxdrostat
Other fourth-line and add-on options: efficacy and tolerability
Medication nonadherence: insured US adults, 2015
“We included 23.8 million hypertensive adults who filled 265.8 million prescriptions for antihypertensive medications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall weighted national nonadherence rate was 31.0%, with greater nonadherence among women versus men, younger versus older adults (aged 18-34 years, 58.1%; aged 65-74 years, 24.4%), fixed-dose combination medication nonusers (31.2%) versus users (29.4%), and by pharmacy outlet type (retail only, 30.7%; any mail order, 19.8%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medication nonadherence: apparent treatment-resistant hypertension
“From an initial discovery of 921 studies, we identified 24 studies that measured medication adherence for patients with uncontrolled BP despite being prescribed three or more antihypertensive medications of different classes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“By using a random effects model, the pooled prevalence of nonadherence was 31.2%” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“with nonadherence rates ranging from 3.3 to 86.1%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuation and low adherence after treatment initiation: Medicare beneficiaries
“Between 2007 and 2012, 41,135 Medicare beneficiaries in the 5% sample initiated antihypertensive medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Discontinuation was stable over the study period (21.0% in 2007 and 21.3% in 2012; p-trend=0.451).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Low adherence decreased from 37.4% in 2007 to 31.7% in 2012 (p-trend<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Therapeutic inertia
Place in treatment, anticipated use, and care setting
Summary
- Guideline sequence: The 2025 AHA/ACC guideline starts drug treatment of resistant hypertension with an ACE inhibitor or ARB, a calcium channel blocker, and a diuretic, then adds spironolactone (25 to 50 mg/day) as the fourth drug. Amiloride (10 to 20 mg) is the alternative when spironolactone or eplerenone is not tolerated, followed by beta-blockers, alpha blockers, central sympatholytic drugs, direct vasodilators, or aprocitentan. Renal denervation is reserved for adults with intolerable side effects to optimal drug regimens. ICER summarizes the guideline as recommending referral to a specialist for a known or suspected secondary cause or when blood pressure remains uncontrolled after more than 6 months of treatment.
- Anticipated use: Mineralys submitted the NDA for the treatment of hypertension in combination with other antihypertensive drugs, the same wording as the first part of the BAXFENDY (baxdrostat) indication, which adds adults not adequately controlled on other agents. Mineralys describes its target as third-line or later treatment, with resistant hypertension as the initial segment and a “beachhead at fourth line”. Manufacturers told ICER that they view aldosterone synthase inhibitors as appropriate for third- or fourth-line therapy regardless of whether a third first-line agent had been tried.
- ICER populations and clinical input: ICER assessed three populations: resistant hypertension not at goal; blood pressure above goal on two drugs with intolerance of a third first-line agent; and blood pressure above goal on two drugs without a trial of a third first-line agent. ICER consulted five clinical experts (two internists, two cardiologists, one nephrologist), who identified mineralocorticoid receptor antagonists such as spironolactone as the preferred option for people who remain uncontrolled despite regular medication use.
- Care setting: Lorundrostat is orally administered. Mineralys estimates about 60,000 physicians write half of the third-line or later prescriptions, with a 60/40 split between primary care and specialists, most of whom are cardiologists. The guideline assigns routine and complex hypertension care to primary care physicians and cardiologists, and complex care involving secondary causes or resistant hypertension to nephrologists, endocrinologists, and hypertension specialists.
Guideline treatment sequence for resistant hypertension
Guideline treatment sequence and specialist referral: ICER summary of the 2025 guideline
Proposed indication: use with other antihypertensive drugs
Labeled place of the first aldosterone synthase inhibitor
Manufacturer positioning: third-line or later use
Manufacturer positioning reported by ICER
Clinical expert views reported by ICER
Care setting: prescribers targeted by the manufacturer
Care setting: roles of the hypertension care team
Heterogeneity of treatment effect
Summary
- Lorundrostat: In Launch-HTN, the blood pressure effect of lorundrostat 50 mg was consistent across age, sex, race, body mass index, and number of background antihypertensive drugs. The placebo-adjusted change in office systolic blood pressure at week 6 was −8.8 mm Hg in participants taking 2 drugs and −9.0 mm Hg in those taking 3 or more. In a Launch-HTN analysis by chronic kidney disease (CKD) status, the placebo-adjusted reduction at week 12 was −12.2 mm Hg without CKD and −9.6 mm Hg with CKD stages 1 to 3; confirmed serum potassium above 6.0 mmol/L occurred in 3 (2.4%) participants with CKD and none without CKD. In the phase 2 Target-HTN trial, prespecified exploratory subgroups showed larger reductions in participants with a body mass index above 30 than in those with a body mass index of 25 to 30, and attenuated reductions in participants not taking a diuretic; participants with nonsuppressed plasma renin (exploratory cohort 2) had a reduction similar to those with suppressed renin at 100 mg. In Explore-OSA, participants with obesity and moderate-to-severe obstructive sleep apnea had a placebo-adjusted office systolic reduction of 10.1 mm Hg in the parallel-arm analysis.
- Class evidence: ICER reported consistent baxdrostat effects across all prespecified subgroups in BaxHTN and Bax24, similar aldosterone synthase inhibitor effects in participants taking two versus three or more background drugs, and no differential blood pressure lowering by mineralocorticoid antagonists between resistant and non-resistant hypertension. In a randomized crossover trial in resistant hypertension, spironolactone lowered blood pressure most across the distribution of baseline plasma renin, with a margin of superiority many-fold greater at the lower end, and plasma renin and the aldosterone-to-renin ratio predicted the home systolic response.
- Limits of the evidence: The pivotal aldosterone synthase inhibitor trials excluded people with advanced CKD. ICER reports hearing that differences in treatment effect by race or ethnicity are small and not likely to be clinically significant. Target-HTN subgroup analyses were exploratory.
Lorundrostat subgroups in Launch-HTN: age, sex, race, body mass index, and number of background drugs
“The efficacy of lorundrostat for lowering BP was consistent across age, sex, race, BMI, and number of prescribed antihypertensive medications participants were taking (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −8.8 mm Hg (97.5% CI, −14.8 to −2.9 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 2 prescribed antihypertensive medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −9.0 mm Hg (97.5% CI, −14.0 to −4.1 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 3 or more antihypertensive medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A comparable reduction in office systolic BP was observed across the continuum of BMI represented in the trial; 91.6% of participants had a BMI of 25 or greater.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lorundrostat by chronic kidney disease status in Launch-HTN
Lorundrostat by chronic kidney disease stage in Launch-HTN: placebo-adjusted change at week 12
| CKD stage | Lorundrostat 50 mg participants | Placebo-adjusted AOSBP change, mm Hg (95% CI) | Week 12 % with AOSBP <130 mmHg, lorundrostat 50 mg |
|---|---|---|---|
| No CKD | “N=406” | “-12.2 (-17.1, -7.3)” | “48.0” |
| Stage 1 | “N=58” | “-10.6 (-18.6, -2.6)” | “50.6” |
| Stage 2 | “N=31” | “-7.6 (-16.5, 1.4)” | “28.4” |
| Stage 3 | “N=38” | “-10.1 (-21.1, 1.0)” | “47.0” |
Lorundrostat by obesity and diuretic use in Target-HTN
“Analysis of the primary end point was repeated in each prespecified subgroup, and these analyses were considered exploratory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with a BMI greater than 30 randomized to 50 mg once daily of lorundrostat demonstrated a −16.7 mm Hg (90% CI, −25.5 to −7.9 mm Hg) change in systolic AOBP compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals with a BMI of 25 to 30, the BP changes were 2.2 mm Hg (90% CI, −7.4 to 11.8 mm Hg) and −4.5 (90% CI, −14.5 to 5.5 mm Hg) for the 50-mg and 100-mg once-daily doses, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blood pressure decreases were attenuated among participants not taking a diuretic” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lorundrostat by plasma renin status in Target-HTN
“Participants with PRA of greater than 1.0 ng/mL/h (cohort 2) randomized to 100 mg once daily of lorundrostat demonstrated a similar change in mean systolic AOBP of −11.4 (SD, 2.5) mm Hg compared with those randomized to 100 mg once daily with suppressed plasma renin in cohort 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because cohort 2 was an exploratory end point, no formal statistical testing was performed comparing lorundrostat with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lorundrostat in obstructive sleep apnea with obesity
Number of background antihypertensive drugs: class evidence used by ICER
Spironolactone response by plasma renin
“Spironolactone was the most effective blood pressure-lowering treatment, throughout the distribution of baseline plasma renin; but its margin of superiority and likelihood of being the best drug for the individual patient were many-fold greater in the lower than higher ends of the distribution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Advanced chronic kidney disease excluded from pivotal trials
Care management intervention strategies
Summary
- Team-based care: The 2025 AHA/ACC guideline describes multidisciplinary team-based care, including pharmacists, nurses, and community health workers, as effective in addressing barriers to blood pressure control. In a meta-analysis of 19 studies (5,993 participants), team-based care lowered systolic blood pressure at 12 months by 10.5 mm Hg with non-physician medication titration and 5.0 mm Hg with physician titration compared with usual care; the non-physician titration strategy was estimated at $4,400 per QALY gained over 10 years.
- Pharmacist management: In a cluster-randomized trial of 319 Black men recruited in 52 barbershops, pharmacist-led drug management reduced systolic blood pressure by 21.6 mm Hg more than the control approach at 6 months. A model estimated that 50% uptake of pharmacist prescribing would save $1.137 trillion and 30.2 million life years over 30 years.
- Home blood pressure monitoring and adherence: The guideline states that home blood pressure monitoring improves office blood pressure control when combined with other interventions, and lists dose consolidation, single-pill combinations, pharmacist education, home monitoring with feedback, shared decision-making, and medication synchronization and reminders as evidence-based adherence strategies.
Team-based care: guideline
Team-based care: meta-analysis and cost-effectiveness
“Among 19 studies comprising 5,993 participants, the 12-month SBP change vs. usual care was −5.0 (95% confidence interval: −7.9 to −2.2) mmHg for TBC with physician titration and −10.5 (−16.2 to −4.8) mmHg for TBC with non-physician titration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Relative to usual care at 10 years, TBC with non-physician titration was estimated to cost $95 (95% uncertainty interval: -$563 to $664) more per patient and gain 0.022 (0.003 to 0.042) QALYs, costing $4,400/QALY gained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacist-led management: barbershop trial in Black men
“We enrolled a cohort of 319 black male patrons with systolic blood pressure of 140 mm Hg or more from 52 black-owned barbershops (nontraditional health care setting) in a cluster-randomized trial in which barbershops were assigned to a pharmacist-led intervention (in which barbers encouraged meetings in barbershops with specialty-trained pharmacists who prescribed drug therapy under a collaborative practice agreement with the participants’ doctors) or to an active control approach (in which barbers encouraged lifestyle modification and doctor appointments).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacist prescribing: US cost-effectiveness
“In this simulated cost-effectiveness analysis of a 5-state Markov model, 50% uptake of a pharmacist-prescribing intervention to improve blood pressure control was associated with a $1.137 trillion in cost savings and could save an estimated 30.2 million life years over 30 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Home blood pressure monitoring
Patient-reported needs: dietary counseling and peer education
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary
- Benefit per unit of blood pressure reduction: An individual participant-level meta-analysis of 48 trials found that each 5 mm Hg reduction in systolic blood pressure lowered the risk of major cardiovascular events by about 10%, with reductions of 13% for stroke, 13% for heart failure, 8% for ischemic heart disease, and 5% for cardiovascular death, irrespective of prior cardiovascular disease. A meta-analysis of 123 studies (613,815 participants) found that each 10 mm Hg reduction lowered major cardiovascular events (relative risk 0.80), coronary heart disease (0.83), stroke (0.73), heart failure (0.72), and all-cause mortality (0.87), with no significant effect on renal failure. FDA guidance attributes these benefits largely to the decrease in blood pressure itself across drug classes.
- Lorundrostat: In Launch-HTN, lorundrostat 50 mg lowered office systolic blood pressure by 9.1 mm Hg more than placebo at week 6. No trial of lorundrostat or baxdrostat reporting cardiovascular, kidney, or mortality outcomes was identified; the placebo-controlled Launch-HTN comparison lasted 12 weeks.
- Blood pressure as a surrogate: ICER states that blood pressure is a surrogate marker, that not all blood pressure drugs have the same effect on major adverse cardiovascular events and their effects on mortality are inconsistent, and that longer-term data are needed to determine the effect of aldosterone synthase inhibitors on patient-important outcomes. A review of FDA surrogate endpoints found 10 meta-analyses with inconsistent evidence on the strength of association between blood pressure reductions and cardiovascular outcomes and all-cause mortality. The Explore-OSA investigators state that a longer-term cardiovascular outcomes trial of lorundrostat should be considered.
Cardiovascular benefit per 5 mm Hg reduction in systolic blood pressure
“In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On average, a 5 mm Hg reduction of systolic blood pressure reduced the risk of a major cardiovascular event by about 10%; the corresponding proportional risk reductions for stroke, heart failure, ischaemic heart disease, and cardiovascular death were 13%, 13%, 8%, and 5%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular benefit per 10 mm Hg reduction in systolic blood pressure
“We identified 123 studies with 613,815 participants for the tabular meta-analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Every 10 mm Hg reduction in systolic blood pressure significantly reduced the risk of major cardiovascular disease events (relative risk [RR] 0·80, 95% CI 0·77-0·83), coronary heart disease (0·83, 0·78-0·88), stroke (0·73, 0·68-0·77), and heart failure (0·72, 0·67-0·78), which, in the populations studied, led to a significant 13% reduction in all-cause mortality (0·87, 0·84-0·91).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the effect on renal failure was not significant (0·95, 0·84-1·07).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was no clear evidence that proportional risk reductions in major cardiovascular disease differed by baseline disease history, except for diabetes and chronic kidney disease, for which smaller, but significant, risk reductions were detected.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure reduction as the basis of cardiovascular benefit: FDA guidance
Blood pressure reduction as the basis of cardiovascular benefit: ICER background
Blood pressure as a surrogate marker: strength of evidence
“Of 5541 records screened, 10 meta-analyses offered inconsistent evidence on the strength of association between reductions in systolic or diastolic blood pressure and improvements in cardiovascular outcomes and all-cause mortality (eTable 10 and eFigure 26 in Supplement 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lorundrostat blood pressure effect in the phase 3 trial
“For the pooled 50 mg of lorundrostat group (n = 808), the least-squares mean change in automated office systolic BP at week 6 was −16.9 mm Hg (95% CI, −19.0 to −14.9 mm Hg) vs −7.9 mm Hg (95% CI, −11.5 to −4.2 mm Hg) for the placebo group (least-squares mean difference, −9.1 mm Hg [95% CI, −13.3 to −4.9 mm Hg]; P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First, the efficacy and safety of lorundrostat compared with placebo was evaluated for only 12 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote